Outcomes of Enteral Feeding in Motor Neurone Disease by Chhetri, Suresh Kumar
  
 
Outcomes of Enteral Feeding in Motor 
Neurone Disease 
 
By 
Suresh Kumar Chhetri  
 
 
A thesis submitted in partial fulfilment for the requirements for the 
degree of   MD (by Research) 
at the University of Central Lancashire 
 
 
September 2015 
  
 
 
 
 
 
“When [no therapy] avails to ward  
off the fatal ending, it is still no  
small portion of [the physician's] art  
to rid his patient's  
path of thorns if he cannot  
make it bloom with roses.” 
-Alfred Stille, “An address delivered to the medical classes 
of the University of Pennsylvania on withdrawing from his 
chair, April 10, 1884.” Medical News. 1884; 44:433-38. 
i 
 
DECLARATION 
This thesis is an original piece of work. No portion of the work referred to in the thesis 
has been submitted in support of an application for another degree or qualification of 
this or any other university. 
 
Signed 
 
 
 
 
 
 
 
 
 
ii 
 
ABSTRACT 
Motor Neurone Disease (MND) is a fatal neurodegenerative disease of unknown 
aetiology characterised by the degeneration of motor neurones leading to progressive 
wasting and weakness of the bulbar, limb and respiratory muscles.  Symptomatic 
treatment remains the cornerstone of management.  Malnutrition is a common 
occurrence and an independent risk factor for worse prognosis. Clinical guidelines 
recommend enteral feeding when there is deterioration in nutritional status and/or 
dysphagia. However, it remains unclear whether enteral feeding offers any survival 
advantage. Moreover, the impact of enteral feeding on patients’ quality of life remains 
unknown.  This study was undertaken to assess the impact of enteral feeding on survival 
and quality of life of patients with MND and describe the clinico-demographic 
characteristics of MND in Lancashire and South Cumbria in North West England.  
The study has both retrospective and prospective arms. The retrospective study was 
undertaken by reviewing the Preston MND database and case notes to examine the 
demographic, clinical and survival characteristics of MND in Lancashire and South 
Cumbria.  The prospective study was undertaken over a period of three years to explore 
the perspectives of 21 patients with enteral feeding and its impact on their quality of 
life.  
The overall crude incidence of MND was 3.15 per 100,000. The mean age of onset was 
67.28 (S.D. 11.06; range 22.78-93.06) years. Median overall illness duration was 1.98 
(range 1.18-3.05) years. The presentation was limb onset in 62.1% cases and bulbar 
onset in 37.9% cases. A total of 91 (26.8%) patients received enteral feeding of which 
67.0% were bulbar onset. Enteral feeding was not associated with a statistically 
significant survival advantage (χ2 (1) = 1.73, p = 0.19).  
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Enteral feeding was associated with improved quality of life, despite the attendant 
inconveniences. Enteral feeding was perceived as being essential to survival by some 
participants while others reported a sense of relief and security that their nutritional 
needs were met. The body mass index stabilised following enteral feeding.  A key 
finding, relevant for clinical practice, is that most study subjects acknowledged the 
importance of enteral feeding and a vast majority did not wish for the feeding tube to be 
removed, indicating a positive attitude towards enteral feeding.   
In conclusion, this study demonstrates a positive impact of enteral feeding on quality of 
life but not on survival. The lack of survival advantage should however, not dissuade 
clinicians from offering enteral feeding to patients with MND who manifest dysphagia 
and/or malnutrition. Even if enteral feeding does not add months to life, this study 
provides preliminary evidence that that it helps to add life to months.  
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1.1 Background 
Motor Neurone Disease (MND) is a fatal neurodegenerative disease of unknown 
aetiology characterised by the degeneration of motor neurones in the primary motor 
cortex, corticospinal tracts, brainstem and anterior horn cells of the spinal cord 
(Hardiman, 2000; Miller et al., 2009). The clinical presentation results from progressive 
wasting and weakness of the bulbar, limb and respiratory muscles (Kiernan et al., 2011). 
The condition can be sporadic or familial (Wijesekera and Leigh, 2009).  
The median survival from symptom onset to death varies from 20 to 48 months (Beghi 
et al., 2011). In the absence of a cure, symptomatic and palliative treatment remains the 
mainstay of management (Andersen et al., 2012). Malnutrition is a major concern and 
an independent prognostic factor for survival (Desport et al., 1999; Marin et al., 2011).  
Treatment guidelines recommend consideration of enteral nutrition through a feeding 
tube in patients at risk of malnutrition or dysphagia (Andersen et al., 2012; Miller et al., 
2009). However, the evidence for survival advantage with enteral feeding is 
inconclusive (Katzberg and Benatar, 2011). Furthermore, there is little evidence to 
support or refute enteral feeding for improving quality of life (QOL) of patients with 
MND (Katzberg and Benatar, 2011). 
The aims of the thesis were to assess the outcomes of enteral feeding and describe the 
demographic and clinical characteristics of MND in Lancashire and South Cumbria in 
North West England. The thesis begins with an overview of MND and its management, 
thereby setting the scene for use of enteral feeding in MND.   
This thesis is divided into five chapters. Chapter 1 begins with a review of relevant 
literature and rationale for the research and further discusses the nomenclature, 
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epidemiology, aetio-pathogenesis, clinical characteristics, diagnosis and management of 
MND. Chapter 2 systematically reviews all retrospective and prospective studies 
investigating the impact of enteral feeding on survival, nutritional status and QOL of 
patients with MND. Chapter 3 describes the demographic, clinical and survival 
characteristics of MND in Lancashire and South Cumbria.  Chapter 4 presents the 
findings of a prospective study aimed at investigating the impact of enteral feeding on 
QOL of MND patients. Chapter 5 discusses the results in the broader context of extant 
literature, draws conclusions and proposes recommendations for clinical practice and 
future research. These chapters are followed by scope for future studies and references. 
 
1.2 History and Nomenclature  
The nomenclature of motor neurone disease has evolved over a century reflecting 
advances in clinico-pathological concepts of the disorder (Rowland, 2001). In 1850, 
Aran described patients with muscle weakness and atrophy and termed the condition 
‘atrophie musculaire progressive’ or progressive muscular atrophy (Aran, 1850). 
However, Duchenne (1883) claimed that the publication by Aran was based on the data 
from electrical stimulation studies that he had undertaken and communicated to Aran. 
As a compromise, contemporary neurologists credited both by referring to the condition 
as Aran-Duchenne disease or Duchenne-Aran disease (Visser et al., 2008).   
Amyotrophic lateral sclerosis (ALS), the classical variant of MND was initially 
described by Jean-Martin Charcot, the French neurobiologist and physician, as a distinct 
neurological disorder with characteristic pathological findings (Charcot, 1881). In a 
series of lectures, he described the clinical and pathological features of the condition 
based upon his clinico-pathological observations of patients with muscle wasting and 
weakness (Charcot, 1881).  
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‘Amyotrophy’ refers to muscle atrophy, weakness and fasciculations secondary to the 
degeneration of anterior horn cells, reflecting lower motor neurone (LMN) involvement 
(Rowland and Shneider, 2001). The lower motor neurones originate in the cranial nerve 
motor nuclei of brainstem or the anterior horn cells of spinal cord and innervate skeletal 
muscles (Damjanov, 2000). They are the final common pathway through which the 
nervous system transmits neural information to the skeletal muscles (Figure 1.1). Lower 
motor neurone syndrome results from damage to the LMN cell bodies or their 
peripheral axons.   
 
 
Figure 1.1: The pathways of upper and lower motor neurones (Taken from Damjanov, 
2000) 
‘Lateral sclerosis’ refers to the hardening or sclerosis of the lateral corticospinal tracts 
secondary to degeneration and replacement of these upper motor neurone (UMN) tracts 
by gliosis (Rowland and Shneider, 2001). The neurones that originate from the motor 
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cortex of brain and project to the lower motor neurones in brainstem or spinal cord 
through various descending pathways including corticobulbar and corticospinal tracts 
are called upper motor neurones (Damjanov, 2000). Damage to the neural pathway 
anywhere along this trajectory gives rise to UMN syndrome. Primary lateral sclerosis, a 
progressive pure UMN syndrome was first described by Spiller in 1904 (Spiller, 1904). 
Recognising the variable involvement of upper and lower motor neurones in these 
syndromes, Lord Russell Brain introduced the term motor neurone disease to 
encompass a spectrum of disorders including amyotrophic lateral sclerosis, primary 
lateral sclerosis, progressive bulbar palsy and progressive muscular atrophy (Brain, 
1962). The condition is known colloquially as Lou Gehrig's disease, particularly in the 
United States, after the famous New York Yankees baseball player who acquired the 
disease (Brennan, 2012; Kasarskis and Winslow, 1989). In the United Kingdom, motor 
neurone disease is adopted as an umbrella term to refer to all these variants of the illness 
(Swash and Desai, 2000). The common trend internationally is to use the terms 
amyotrophic lateral sclerosis and motor neurone disease interchangeably (Bak and 
Hodges, 2004).  
 
1.3 Epidemiology 
Sporadic MND predominantly affects middle-aged and elderly individuals with the 
mean age of onset varying from 55 to 65 years (Wijesekera and Leigh, 2009). The 
incidence ranges from 1.5 to 2.5 cases per 100,000 per year (Hoppitt et al., 2011; 
Logroscino et al., 2010; Mehal et al., 2013; Traynor et al., 1999). However, the 
incidence rate varies significantly in different age groups. The age adjusted incidence 
rate is less than 1.5 cases per 100,000 per year in the first four decades and increases 
sharply around 40 years of age, reaching its peak of 10  to 15 cases per 100,000 per year 
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between ages 60 and 79. The incidence declines rapidly after 80 years of age 
(Logroscino et al., 2010; Sorenson et al., 2002; Traynor et al., 1999). 
The point prevalence varies from 2.7 to 7.4 per 100,000 (Worms, 2001). The estimated 
lifetime risk of developing MND is approximately 1 in 350 for men and 1 in 472 for 
women (Alonso et al., 2009). For reasons that are not clear, males are affected more 
than females with a male to female ratio of 1.5 (Beghi et al., 2006; McCombe and 
Henderson, 2010; Wijesekera and Leigh, 2009). 
 
1.4 Clinical Presentation  
Motor neurone disease demonstrates marked phenotypic heterogeneity (Table 1.1). The 
presentation may be with progressive weakness and wasting of limb, bulbar or 
respiratory muscles (Chio et al., 2011a; Kiernan et al., 2011). The four major clinical 
phenotypes include amyotrophic lateral sclerosis, progressive bulbar palsy, progressive 
muscular atrophy and primary lateral sclerosis (Kiernan et al., 2011).  
Table 1.1: Table showing the six Motor Neurone Disease Phenotypes  
 
1. Amyotrophic lateral sclerosis (classic variant)  
2. Progressive bulbar palsy 
3. Progressive muscular atrophy 
4. Primary lateral sclerosis 
5. Other rare variants  
a. Flail arm variant  
b. Flail Leg Variant 
6. Familial motor neurone disease 
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Extraocular and sphincter muscles are typically spared, although they may rarely be 
involved in the later stages of the illness (Hardiman et al., 2011). Subtle ocular 
abnormalities including slowing of saccadic eye movements and ocular fixation 
abnormalities can occur and may indicate sub-clinical frontal lobe dysfunction 
(Donaghy et al., 2009; Donaghy et al., 2010). Sensory examination is almost always 
normal and an abnormal sensory examination in the absence of a neurological 
comorbidity should raise suspicion about an alternative diagnosis (Mitchell and Borasio, 
2007). The usual cause of death is respiratory failure (Kiernan et al., 2011). 
 
1.4.1 Amyotrophic Lateral Sclerosis (ALS)  
Approximately 61-70% of patients with MND present with limb onset of the illness, 
characteristic of ALS (Kiernan et al., 2011; Logroscino et al., 2010). The clinical 
diagnosis of ALS rests on the demonstration of LMN and UMN signs (Figure 1.2), 
which spread both within and between four different body regions, and exclusion of 
other mimic syndromes (Brooks, 1994; Brooks et al., 2000). The four body regions 
include bulbar, cervical, thoracic and lumbosacral segments of the central nervous 
system.  However, signs may be absent early in the course of the illness leading to 
diagnostic delays (Cellura et al., 2012; Mitchell et al., 2010). 
Limb clumsiness and muscle weakness of insidious onset may start either distally or 
proximally in the upper or lower limbs (Eisen, 2009; Mitchell and Borasio, 2007; 
Zoccolella et al., 2006). The symptoms are usually asymmetrical at onset and spread 
contiguously over months to become bilateral (Ravits and La Spada, 2009; Vejjajiva et 
al., 1967).  Uncommonly, patients may present with wasting before weakness becomes 
evident (Wijesekera and Leigh, 2009). Patients may notice cramps, muscle twitching or 
fasciculations prior to the onset of weakness but these are rarely the presenting 
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symptoms (Eisen, 2009; Gubbay et al., 1985; Kiernan et al., 2011).   Upper limb onset 
illness presents with reduced muscle strength, poor grip and/or impaired hand dexterity. 
Lower limb onset illness manifests as difficulty in walking, foot drop, tendency to trip 
and heaviness of one or both legs (Eisen, 2009; Kiernan et al., 2011; Norris et al., 
1993).  
 
Figure 1.2:  Both upper and lower motor neurones degenerate in ALS (Taken from 
Tiryaki and Horak, 2014). 
Progressive bulbar involvement affects a vast majority of patients resulting in dysarthria 
and difficulty in swallowing (Gubbay et al., 1985). With disease progression, 70% - 
81% of patients with MND develop dysarthria and dysphagia (Caroscio et al., 1987; 
Greenwood, 2013). The respiratory muscles are commonly involved in the disease 
course leading to respiratory failure (Hardiman et al., 2011).  Respiratory onset of the 
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illness occurs in 3 to 5% of the patients and may present with shortness of breath and 
respiratory failure (Gautier et al., 2010; Shoesmith et al., 2007; Wijesekera and Leigh, 
2009). Median survival is approximately 2.6 years with a 10 year survival rate of 13% 
(Chio et al., 2011a). 
Examination may disclose signs of UMN and LMN degeneration (Brooks, 1994; 
Brooks et al., 2000). UMN signs include spasticity, pyramidal pattern of weakness with 
the limb flexors being more involved than the extensors, brisk deep tendon reflexes or 
preservation of reflexes in a wasted extremity, sustained clonus and extensor plantar 
reflex.  
LMN features include muscle wasting (Figures 1.3 – 1.5), weakness and fasciculations 
(Brooks et al., 2000; Hardiman et al., 2011; Wijesekera et al., 2009). Fasciculations in 
the presence of weakness, particularly if multifocal, is a strong evidence of LMN 
degeneration (Eisen, 2009; Kiernan et al., 2011). Weakness of neck extensors may 
manifest as head drop (Umapathi et al., 2002). 
 
Figure 1.3: Photograph showing marked bilateral wasting of the shoulder girdles, 
pectoral muscles and upper limbs (Taken from Hardiman et al., 2011). 
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Figure 1.4: Photograph showing wasting of the dorsal interossei muscles of the hand 
(printed with patient’s consent). 
 
 
Figure 1.5: Photograph showing wasting of the thenar and hypothenar eminences 
(printed with patient’s consent).  
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Some cases may demonstrate the ‘split hand syndrome’ (Figure 1.6) with preferential 
wasting of the muscles of the lateral border of hand which includes the first dorsal 
interosseous and abductor pollicis brevis (Eisen and Kuwabara, 2012). ALS may rarely 
present as a clinical syndrome of progressive hemiplegia that may ascend from the leg 
or descend from the arm. This phenotype is referred to as the Mills variant or 
hemiplegic ALS (Baumer et al., 2014; Mills, 1900).  
 
 
Figure 1.6: Photograph showing the ‘split hand’ syndrome.  There is wasting of the 
first dorsal interosseous and thenar complex but sparing of the hypothenar muscles 
(black arrows) (Taken from Eisen and Kuwabara, 2012). 
 
1.4.2 Progressive Bulbar Palsy  
Bulbar onset illness presenting with dysarthria and dysphagia occurs in approximately 
20 - 25% of the patients (Haverkamp et al., 1995; Logroscino et al., 2010; Turner et al., 
2010).  Females are more commonly affected and the proportion of patients with bulbar 
onset illness increases with advancing age (Traynor et al., 2000). The initial presenting 
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symptom is usually dysarthria followed by dysphagia (Eisen, 2009; Traynor et al., 
2000).  Similar to limb onset illness, progressive bulbar palsy may manifest with 
clinical features of UMN dysfunction, LMN dysfunction or combination of both (Norris 
et al., 1993; Vejjajiva et al., 1967). 
Bulbar UMN dysfunction results in pseudobulbar palsy which presents with spastic 
dysarthria characterised by slow, strained and effortful speech, slow tongue movements, 
brisk jaw jerk, emotional lability and excessive yawning (Eisen, 2009; Kiernan et al., 
2011; Vejjajiva et al., 1967). Bulbar LMN dysfunction results in bulbar palsy presenting 
with flaccid dysarthria characterised by nasal speech, weakness, fasiculations and 
wasting of the tongue (Figure 1.7).  
A vast majority of patients with bulbar dysfunction develop sialorrhoea due to difficulty 
swallowing saliva.   Bulbar onset illness tends to have a worse prognosis than limb 
onset MND with a median survival of 27 months (Wijesekera and Leigh, 2009). 
 
 
Figure 1.7: Photograph showing wasting of the tongue muscles in bulbar palsy (Taken 
from Kiernan et al., 2011).  
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1.4.3 Primary Lateral Sclerosis 
Primary lateral sclerosis (PLS) is characterized clinically by a progressive pure upper 
motor syndrome in the absence of an alternative disease process (Pringle et al., 1992; 
Singer et al., 2007). PLS is rare, accounting for 1.6 to 4.4% of patients with MND (Le 
Forestier et al., 2001; Pringle et al., 1992).  
Patients present with spastic paresis of insidious onset, usually beginning in the legs, but 
occasionally can manifest with pseudobulbar palsy and UMN features in the arms 
(Gordon et al., 2006; Pringle et al., 1992). The clinical manifestations may remain 
asymmetric for several years (Strong and Gordon, 2005).  Patients report stiffness and 
clumsiness rather than weakness as compared to ALS; when limb weakness occurs, it is 
generally mild and noticed later in the course of illness (Singer et al., 2007). 
The diagnosis rests on demonstration of UMN signs, absence of LMN signs and no 
evidence of denervation on electromyography (EMG), 4 years from the onset of 
symptoms (Gordon et al., 2006). 77% of patients develop clinical or EMG features of 
LMN involvement and hence the diagnosis of PLS should be made only after four years 
of disease duration (Gordon et al., 2006). The prognosis is significantly better than other 
MND phenotypes with a median survival of 13.1 years and a 10 year survival rate of 
71.1% (Chio et al., 2011a; Gordon et al., 2006). 
Neuropathological features of motor neurone degeneration typical of ALS such as 
ubiquitinated inclusions are described in patients with PLS (Tan et al., 2003). It 
therefore remains unclear whether PLS is a distinct nosological entity or a different 
phenotypic manifestation of ALS, as most patients show clinical and/or 
electrophysiological signs of denervation (Le Forestier et al., 2001; Strong and Gordon, 
2005).  
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1.4.4 Progressive muscular atrophy 
Progressive muscular atrophy (PMA) is clinically characterised by signs of LMN 
dysfunction and no signs of UMN involvement (Visser et al., 2008). It is almost always 
of limb onset, but patients may eventually develop bulbar dysfunction (Wijesekera et 
al., 2009). PMA is identified in only 2.4 to 7.6% of cases with sporadic MND (Norris et 
al., 1993; Kim et al., 2009). Patients are more likely to be males with a male to female 
ratio of 2:1 (Kim et al., 2009; Visser et al., 2008). The median survival of 48 to 56 
months is approximately 12 months longer than that of ALS (Kim et al., 2009; Visser et 
al., 2008). 
UMN signs develop in 22 to 35% of patients at some point in the illness, of which 50% 
develop within a year of symptom onset. These patients are then considered to have 
LMN onset ALS (Kim et al., 2009; Visser et al., 2008). Corticospinal tract degeneration 
is present in post mortem pathology in up to 50% of patients with an initial diagnosis of 
PMA indicating that most, if not all, cases of PMA may represent a form of ALS (Ince 
et al., 2003; Kim et al., 2009). 
 
1.4.5 Other Rare Variants 
Flail Arm Variant 
This is a regional LMN variant characterised by bilateral, progressive, predominately 
proximal wasting and weakness of the upper limbs at presentation (Hu et al., 1998; 
Wijesekera et al., 2009). The condition has been described under various names 
including ‘Vulpian-Bernhardt syndrome’ (Gamez et al., 1999), ‘neurogenic man-in-the-
barrel syndrome’ (Katz et al., 1999), ‘flail arm syndrome’ (Hu et al., 1998) and 
‘Brachial amyotrophic diplegia’ (Katz et al., 1999).  
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There may be severe wasting of the shoulder girdle muscles (Figure 1.8) and the arms 
may hang flaccidly by the sides (Wijesekera et al., 2009). There is little or no functional 
involvement of the bulbar musculature and lower limbs in the early stage of the illness. 
Tendon reflexes in the upper limbs are typically reduced or absent, but the lower limbs 
may demonstrate UMN signs (Hu et al., 1998).  
With disease progression, patients may manifest bulbar and lower limb symptoms (Hu 
et al., 1998; Katz et al., 1999). The condition remains restricted to the upper limbs for a 
mean of 20 months after onset (Chio et al., 2011a). The syndrome is significantly more 
common in men with a male to female ratio of 4:1 (Chio et al., 2011a; Wijesekera et al., 
2009). The median survival is 65 months with a five year survival of 52% (Wijesekera 
et al., 2009). 
 
 
Figure 1.8: Photograph showing flail arm variant presenting with proximal and 
symmetrical upper limb wasting (Taken from Kiernan et al., 2011). 
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Flail Leg Variant 
This is a lower extremity, regional LMN variant characterised by progressive distal 
onset weakness and wasting (Wijesekera et al., 2009). The condition has been variously 
termed the pseudopolyneuritic variant, the Marie-Patrikios form or the peroneal form of 
MND (Wijesekera et al., 2009). UMN signs are absent in the earlier stages of the illness 
but may develop with disease progression. Similarly, functional impairment of the 
bulbar musculature and upper limbs is uncommon and may emerge late in the course of 
illness.  The condition remains restricted to the lower limbs for a mean of 16 months 
(Chio et al., 2011a). Males and females are equally affected (Chio et al., 2011a; 
Wijesekera et al., 2009). The median survival is 69 months with a five year survival of 
64% (Wijesekera et al., 2009). 
 
1.4.6 Familial Motor Neurone Disease 
A positive family history of the condition is present in up to 5 to 10% of patients with 
MND (Renton et al., 2014; Rowland and Shneider, 2001). Similar to sporadic MND, 
there is heterogeneity in phenotypic expression and rate of progression, both within and 
between different genes (Ravits et al., 2013; Renton et al., 2014). Most cases are 
inherited in an autosomal dominant pattern, although autosomal recessive forms have 
been described (Renton et al., 2014). The age of onset of familial MND is roughly a 
decade earlier than the sporadic cases (Wijesekera and Leigh, 2009; Williams et al., 
2013). 
The genetic aetiology of two thirds of familial pedigrees has been identified (Renton et 
al., 2014). Major  genes underlying familial MND includes chromosome 9 open reading 
frame 72 (C9orf72), Superoxide Dismutase 1 (SOD1), Transactive response DNA-
binding protein (TARDBP), Fused in sarcoma (FUS), Optineurin (OPTN), Valosin-
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containing protein (VCP), Ubiquilin 2 (UBQLN2), Sequestosome 1 (SQSTM1) and 
Profilin 1 (PFN1) (Ravits et al., 2013; Renton et al., 2014). Mutations in C9orf72, 
SOD1, TARDBP and FUS genes underline approximately two-thirds of familial cases 
(Figure 1.9) (Chio et al., 2014).  
Mutation in C9orf72 gene is responsible for 39% of cases of familial and 7% of 
sporadic MND (Majounie et al., 2012).  The identification of hexanucleotide repeat 
expansion in the C9orf72  gene in 7% of patients without a family history of MND 
challenges the traditional nomenclature of sporadic and familial MND and should not 
be viewed as absolute (Majounie et al., 2012; Renton et al., 2014). 
 
 
Figure 1.9: Pie chart showing genetics of familial Motor Neurone Disease. C9orf72 = 
chromosome 9 open reading frame 72; SOD1 = superoxide dismutase 1; TARDBP = 
transactive response DNA binding protein; FUS = fused in sarcoma (Taken from 
Tiryaki and Horak, 2014). 
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1.5 Aetiology 
The cause of sporadic MND remains unknown. However, given the significant clinical, 
prognostic and genetic heterogeneity (Figure 1.10), the condition is believed to result 
from a complex interplay of genetic and environmental factors (Ravits et al., 2013). For 
reasons that are unclear, substantially increased risk of MND has been reported in 
Italian professional football players (Chio et al., 2005) and military personnel 
(Weisskopf et al., 2005). 
 
Figure 1.10: Flow chart showing the heterogeneity of Motor Neurone Disease  
A range of risk factors including environmental toxins (Malek et al., 2014), occupation 
(Sutedja et al., 2007), physical activities (Veldink et al., 2005), alcohol (de Jong et al., 
2012) smoking and a combination of these risk factors (Pamphlett and Ward, 2012; 
Wang et al., 2011) have been analysed in number of neuroepidemiological studies. The 
findings of these studies have demonstrated little consensus and this may be due to a 
number of factors including small sample sizes, methodological issues and use of 
referral or prevalent cohorts rather than population-based incident cohorts (Hardiman et 
al., 2011; Sutedja et al., 2009).  
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1.6 Pathogenesis 
The pathophysiological mechanisms underlying motor neurone degeneration remains 
unknown but is presumed to be multifactorial (Figure 1.11), with complex interactions 
between genetic and molecular pathways (Pasinelli and Brown, 2006).  The possible 
mechanisms of motor neurone death includes glutamate excitotoxicity, oxidative stress, 
mitochondrial dysfunction, formation of inflammatory cascades,  derangement of 
cytoskeletal elements, impaired axonal transport, deficits in neurotrophic factors, 
aberrant ribonucleic acid (RNA) metabolism, glial cell pathology, apoptosis, 
neurofilament and protein aggregation (Cleveland and Rothstein, 2001; Rothstein, 2009; 
Swarup and Julien, 2011).  
 
 
Figure 1.11: Diagram showing the mechanisms underlying neurodegeneration in MND. 
20 
 
The selective vulnerability of the motor neurones to neurodegeneration also remains a 
mystery. However, it is increasingly becoming obvious from the clinical, prognostic and 
genetic heterogeneity that MND may be a syndrome rather than a single disease entity 
(Ravits et al., 2013). 
 
1.7 Histopathological features   
Motor neurone disease has a distinctive neuropathological signature. The pathological 
hallmarks include loss of motor neurones with astrocytic gliosis and presence of 
intraneuronal inclusions in degenerating neurones and glia (Hirano, 1996; Wijesekera 
and Leigh, 2009). UMN loss is demonstrated by loss of Betz cells in the motor cortex 
and axonal loss in descending motor pathways including the lateral corticospinal tracts 
(lateral sclerosis). There is also loss of lower motor neurones within the anterior horns 
of the spinal cord and brainstem leading to muscle denervation and atrophy 
(amyotrophy) (Hirano, 1996; Wijesekera and Leigh, 2009).  
The neuronal cytoplasmic inclusions include Bunina bodies which are small 
eosniophilic granular inclusions in the anterior horn cells and ubiquitinated protein 
aggregates.  Cytoplasmic inclusions of transactive response DNA binding protein 43 
kDa (TDP-43) are found in a majority of cases of sporadic MND (Geser et al., 2010; 
Majounie et al., 2012). However, TDP-43 is absent in MND associated with pathogenic 
mutations of SOD1 indicating pathogenic heterogeneity (Mackenzie et al., 2007). 
For reasons that are not understood, there is selective sparing of the motor nucleus of 
Onufrowicz in the sacral spinal segment (Wijesekera and Leigh, 2009). There is also 
sparing of the nuclei of the oculomotor, trochlear and abducens nerve (Hirano, 1996; 
Wijesekera and Leigh, 2009).  
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1.8 Diagnostic criteria  
In the absence of a definitive diagnostic test or biomarker, the diagnosis of MND is 
based on typical clinical findings and exclusion of “mimic” syndromes with appropriate 
investigations (Kiernan et al., 2011; Wijesekera and Leigh, 2009). The diagnostic 
criteria for MND have evolved over time and include the following:  
 
1.8.1 El Escorial criteria  
The World Federation of Neurology (WFN) subcommittee on MND proposed the “El 
Escorial” criteria (Table 1.2) for diagnosis of MND after meeting in El Escorial, Spain 
in 1990 (Brooks, 1994).  
Table 1.2: The El Escorial criteria for diagnosis of Motor Neurone Disease/ 
Amyotrophic Lateral Sclerosis (Taken from Brooks, 1994).  
 
 
The diagnosis of Motor Neurone Disease/Amyotrophic Lateral Sclerosis requires: 
The presence of: 
1. Evidence of lower motor neurone degeneration by clinical, 
electrophysiological or neuropathological examination 
2. Evidence of upper motor neurone degeneration by clinical examination 
3. Progressive spread of signs within a region or to other regions 
Together with the absence of: 
1. Electrophysiological evidence of other disease processes that might explain 
the signs of lower motor and/or upper motor neurone degeneration 
2. Neuroimaging evidence of other disease processes that might explain the 
clinical and electrophysiological signs. 
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Clinical evaluation should aim to identify signs of UMN and LMN degeneration in the 
four regions (bulbar, cervical, thoracic and lumbosacral) of central nervous system. 
Clinical features of LMN degeneration include weakness, wasting and fasciculations. 
Features of UMN degeneration include spasticity, brisk deep tendon reflexes and 
extensor plantar response (Brooks, 1994). Progression of signs within a region or to 
other regions is crucial to the diagnosis and six monthly clinical reviews are 
recommended to assess progression (Brooks, 1994).  
Based on the El Escorial criteria, patients can be classified into the following categories 
depending on the clinical probability of diagnosis (Brooks, 1994):  
a. Definite amyotrophic lateral sclerosis/motor neurone disease:   
Clinical evidence of UMN and LMN signs in the bulbar region and at least two of the 
other spinal regions or the presence of UMN and LMN signs in three spinal regions. 
b. Probable amyotrophic lateral sclerosis/motor neurone disease:  
Clinical evidence of UMN and LMN signs in at least two regions with some UMN signs 
rostral to the LMN signs.  
c. Possible amyotrophic lateral sclerosis/motor neurone disease:  
Clinical evidence of UMN and LMN signs in only one region or UMN signs only in 2 
or more regions or LMN signs are rostral to UMN signs.   
d. Suspected amyotrophic lateral sclerosis/motor neurone disease:   
Clinical evidence of LMN signs in 2 or more regions. However, there may be 
pathological evidence of UMN involvement at autopsy.  
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1.8.2. Revised El Escorial or Airlie House diagnostic criteria 
The increasing recognition of the importance of electrophysiological data and the need 
to improve diagnostic sensitivity led to revision of the ‘El Escorial’ criteria (Brooks et 
al., 2000). Following a meeting in Airlie House, Virginia in 1998, electrophysiological 
data were incorporated into the diagnostic algorithm and the revised criteria were 
renamed the ‘revised El Escorial’ diagnostic criteria (Brooks et al., 2000). Based on the 
revised criteria, patients can be classified into 'Clinically definite', 'Clinically probable', 
'Clinically probable-laboratory supported' and 'Clinically possible' categories (Table 
1.3).  
All categories except the 'Clinically probable-Laboratory supported' are defined in the 
same way as in the El Escorial criteria. A diagnosis of 'Clinically probable-laboratory 
supported' MND can be made in the presence of  UMN and LMN signs in only one 
region or UMN signs in only one region and LMN signs defined by EMG in at least 2 
regions.  
EMG should show evidence of active and chronic denervation (Brooks et al., 2000). 
Signs of acute denervation include fibrillation potentials and positive sharp waves. 
Signs of chronic denervation include fasciculation potentials, reduced interference 
pattern with firing rates higher than 10 hertz and unstable motor unit potentials. These 
changes must be present in at least two or more muscles innervated by different nerve 
roots and peripheral nerves in cervical and lumbosacral regions and in one muscle in the 
brainstem and thoracic regions (Brooks et al., 2000).   
The ‘suspected amyotrophic lateral sclerosis’ category has been deleted in the revised 
criteria as the  diagnosis of MND may not be necessarily certain for entry into a 
research study (Brooks et al., 2000). 
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Table 1.3: The revised El Escorial criteria for diagnosis of Motor Neurone Disease/ 
Amyotrophic Lateral Sclerosis: categories of diagnostic certainty (Taken from Brooks et 
al., 2000).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.8.3. Awaji criteria 
The revised El Escorial diagnostic criteria have been criticised for being too stringent 
and 22% of patients with MND may die without achieving a diagnostic category higher 
 
Clinically Definite  
 Upper and lower motor neurone signs in the bulbar region and at least two 
spinal regions or 
 Upper and lower motor neurone signs in three spinal regions. 
Clinically Probable 
 Upper and lower motor neurone signs in at least two regions with some 
upper motor neurone signs rostral to the lower motor neuron signs.  
Clinically probable-laboratory supported 
 Upper and lower motor neurone signs in only one region, or 
 Upper motor neurone signs in only one region and lower motor neurone 
signs defined by electromyography in at least 2 regions. 
Clinically Possible 
 Upper motor and lower motor neurone signs in only one region, or 
 Upper motor neurone signs alone in 2 or more regions, or  
 Lower motor neurone signs are rostral to upper motor neurone signs, and 
 The diagnosis of ‘clinically Probable – Laboratory supported’ category 
cannot be proven with investigations.  
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than clinically possible (Traynor et al., 2000). Moreover, the clinical and EMG 
abnormalities cannot be combined in a single limb and many muscles do not show 
fibrillation potentials and positive sharp waves leading to diagnostic delays (de 
Carvalho et al., 2008). 
In order to determine the efficient use of electrophysiological data, an international 
consensus meeting was held in Awaji Island, Japan in 2006 (de Carvalho et al., 2008).  
The ‘Awaji criteria’ proposed that electrophysiological evidence for LMN dysfunction 
should be assigned equal diagnostic significance to the clinical signs of LMN 
degeneration.   Although the revised El Escorial diagnostic criteria noted fasciculation 
potential as a characteristic feature of MND, they were not acknowledged as evidence 
of active denervation (Brooks et al., 2000). In the Awaji criteria, fasciculation potentials 
associated with signs of reinnervation are considered equivalent to fibrillation potentials 
and positive sharp waves as evidence of acute denervation (de Carvalho et al., 2008). 
This has rendered the ‘clinically probable – laboratory supported ALS’ category 
redundant, and is based on the observation that EMG is an extension of clinical 
examination (de Carvalho et al., 2008). Based on the Awaji criteria, the diagnostic 
categories include ‘clinically definite', 'clinically probable' and 'clinically possible’ 
motor neurone disease.  
A systematic review of eight studies comparing the Awaji criteria with revised El 
Escorial diagnostic criteria suggests improvement in diagnostic sensitivity from 62.2% 
to 81.1% with no change in specificity, which remains at 98% (Costa et al., 2012). 
However, many studies evaluating the Awaji criteria have various methodological 
limitations and report conflicting findings (Benatar and Tandan, 2011). For instance, 
one of the papers included in the systematic review reported increase in diagnostic 
sensitivity from 57% to 87% by using the Awaji criteria (Chen et al., 2010). However 
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this increase is apparent rather than real and resulted from exclusion of the 'clinically 
probable-laboratory supported' category as defined by the revised El Escorial as genuine 
cases of MND. The Awaji criteria has also been criticised for being developed on the 
basis of expert opinion rather than empirical or high quality data and the revised El 
Escorial criteria continues to be widely used in clinical and research studies (Benatar 
and Tandan, 2011).  
 
1.9 Differential diagnosis 
Differential diagnostic considerations and pertinent investigations are dictated by the 
phenotype and clinical context of an individual patient.  The absence of disease 
progression and atypical clinical features, for instance visual, sensory or sphincter 
disturbances (Table 1.4) should trigger a search for ‘mimic syndromes’ (Traynor et al., 
2000). The differential diagnosis is broad, particularly early in the course of illness 
(Kiernan et al., 2011; Traynor et al., 2000; Visser et al., 2008). Table 1.5 outlines the 
‘MND mimics’ and investigations appropriate for the condition.  
Table 1.4: Table outlining the clinical findings inconsistent with the diagnosis of motor 
neurone disease (Taken from Brooks, 1994) 
 
 
 
1. Sensory dysfunction. 
2. Sphincter abnormalities. 
3. Autonomic nervous system dysfunction. 
4. Anterior visual pathway abnormalities. 
5. Movement abnormalities associated with probable Parkinson’s disease.   
6. Cognitive abnormalities associated with clinical Alzheimer’s disease. 
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Table 1.5: Table showing the differential diagnosis of motor neurone disease and 
relevant investigations (Adapted from Kiernan et al., 2011; Traynor et al., 2000; Visser 
et al., 2008) 
 
Structural Disorders 
 Syringomyelia or syringobulbia (Magnetic resonance imaging of the 
spine/brain) 
 Cervical myelopathy (Magnetic resonance imaging of cervical spine) 
 Multi-level spinal cord and root compression by disc or tumour (Magnetic 
resonance imaging of the spine) 
 Post irradiation myelopathy and/or plexopathy (Magnetic resonance imaging 
of the spine, nerve conduction studies, EMG) 
 Tumour of the brain/spinal cord (Magnetic resonance imaging of the  
brain/spinal cord) 
 Cerebrovascular disease (Magnetic resonance imaging of the brain)  
 Foramen magnum lesions (Magnetic resonance imaging of the brain) 
 
Other Motor neurone disorders  
 Spinal muscular atrophy (Survival motor neurone gene deletion assay) 
 Post-polio syndrome (History, nerve conduction studies, EMG) 
 Hirayama disease/ Monomelic spinal muscular atrophy (Magnetic resonance 
imaging of the cervical spine, nerve conduction studies, EMG) 
 
Hereditary conditions 
 Spinobulbar muscular atrophy/Kennedy disease (Genetic test) 
 Hereditary spastic paraparesis (Genetic test)  
 Facioscapulohumeral muscular dystrophy (Genetic test) 
 Hexosaminidase deficiency (White-cell enzyme testing) 
 Acid maltase deficiency (Dried blood spot, muscle biopsy, genetic test)  
 Adrenomyeloneuropathy (Very long chain fatty acids, serum cortisol) 
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Dysimmune and/or inflammatory conditions 
 Multifocal motor neuropathy (Nerve conduction studies, EMG, ganglioside 
antibodies)  
 Chronic inflammatory demyelinating polyneuropathy (Nerve conduction 
studies, EMG, lumbar puncture) 
 Cramp-fasciculation syndrome/ Neuromyotonia (Nerve conduction studies, 
EMG, voltage-gated potassium channel antibody) 
 Myasthenia gravis (Acetylcholine receptor antibodies, anti-muscle specific 
kinase antibody, EMG) 
 Lambert-Eaton myasthenic syndrome (EMG, voltage-gated calcium channel 
antibody) 
 Inclusion body myositis (Nerve conduction studies, EMG, creatine kinase, 
muscle biopsy) 
 Polymyositis (Nerve conduction studies, EMG, creatine kinase, muscle 
biopsy) 
 Multiple sclerosis (Magnetic resonance imaging  of the brain/spinal cord, 
cerebrospinal fluid analysis, visual evoked potentials) 
 Paraneoplastic disorders (Paraneoplastic antibodies, relevant imaging) 
 
Metabolic/Endocrine/Toxic 
 Hyperthyroidism (Thyroid function tests) 
 Hyperparathyroidism (Calcium, phosphate and parathyroid hormone)  
 Heavy metal intoxication (History and relevant analysis) 
 Subacute combined degeneration (Vitamin B12 concentrations) 
 
Infections 
 Human immunodeficiency virus (Serology) 
 Human T-lymphotropic virus-1 (HTLV-1)  (Serology) 
 Tabes dorsalis (Syphilis serology) 
 Lyme disease (Lyme serology) 
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1.10 Associated conditions 
MND has been reported in association with a number of malignancies including 
lymphomas, breast and lung cancer, possibly as a paraneoplastic manifestation (Corcia 
et al., 2014). Co-existence of MND with Huntington’s disease, a trinucleotide repeat 
disorder has also been described raising the possibility of a genetic or epigenetic 
relationship (Chhetri et al., 2014; Tada et al., 2012).  
MND has also been reported in association with a spectrum of autoimmune conditions 
including bronchial asthma, coeliac disease, young onset diabetes mellitus, multiple 
sclerosis, myasthenia gravis, myxoedema, polymyositis, Sjögren syndrome, systemic 
lupus erythematosus, voltage gated potassium antibody and ulcerative colitis (Chhetri et 
al., 2015; Turner et al., 2013). These associations raise the possibility of shared genetic 
or environmental risk factors between the reported conditions and MND (Turner et al., 
2013). 
 
1.11 Investigations 
In the absence of a definitive diagnostic test, the diagnosis of MND remains a clinical 
one (Brooks et al., 2000; Hardiman et al., 2011). Investigations are undertaken to 
support the clinical diagnosis and exclude other MND ‘mimics’ (Table 1.5), which may 
be potentially treatable (Traynor et al., 2000).   
EMG and nerve conduction studies are important ancillary tools in the investigation of 
suspected MND to look for evidence of denervation and reinnervation (de Carvalho et 
al., 2008; Swash, 2000). These studies will also help to exclude other mimics including 
multifocal motor neuropathy and a spectrum of axonal and demyelinating neuropathies 
(Table 1.5). 
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Transcranial magnetic stimulation and central motor conduction studies are not 
performed routinely but allows non-invasive identification of subclinical UMN 
dysfunction (Wijesekera and Leigh, 2009).  Neuroimaging studies including magnetic 
resonance imaging of the brain and cervical spine helps to exclude other differential 
diagnosis including syringomyelia and structural causes of myeloradiculopathy, for 
instance spinal cord compression (Table 1.5).  
Blood tests including full blood count, erythrocyte sedimentation rate, C-reactive 
protein, human immunodeficiency virus serology, syphilis serology, serum protein 
electrophoresis, creatine kinase, antiglycolipid antibodies, renal, liver and thyroid 
function tests are important in excluding infective, inflammatory, dysimmune, 
metabolic and endocrine conditions that may potentially mimic MND  (Kiernan et al., 
2011; Traynor et al., 2000; Visser et al., 2008).   
The need for cerebrospinal fluid examination will be dictated by suspicion of an 
inflammatory pathology, for instance demyelinating neuropathy.  Genetic testing for the 
common mutations may be required, if familial disease is suspected (Hardiman et al., 
2011; Kiernan et al., 2011; Wijesekera and Leigh, 2009). 
 
1.12 Diagnostic delays and errors 
Diagnostic delays are not uncommon in MND. The median delay from symptom onset 
to diagnosis is approximately 12 months by which time the disease is halfway through 
its trajectory (Cellura et al., 2012; Mitchell et al., 2010). This has significant 
implications in accessing appropriate care and management. Unusual clinical 
presentations, a broad differential, low index of suspicion, delays in referral to  a 
neurologist, reluctance to give a devastating diagnosis before it is absolutely certain and 
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misinterpretation of neurophysiological or neuroradiological findings are common 
causes of diagnostic delays (Chio, 1999; Gelinas, 1999; Mitchell et al., 2010). 
One consequence of the need to make an early clinical diagnosis is the risk of 
misdiagnosis which ranges from 7.3 to 8% and this has far-reaching implications, 
including missing a potentially curative condition like multifocal motor neuropathy or 
compressive cervical myelopathy (Davenport et al., 1996; Traynor et al., 2000). A 
thorough clinical approach combined with rational and assiduous application of tailored 
investigations may allow a significant reduction in diagnostic delays and errors (Cellura 
et al., 2012; Traynor et al., 2000).  
 
1.13 Prognosis 
The prognosis and rate of deterioration is highly variable (Caroscio et al., 1987). The 
median survival from onset of symptoms to death varies from 20 to 48 months (Beghi et 
al., 2011). The 3 and 5 year survival rates are reported to be approximately 48% and 
24% respectively and about 4% survive longer than 10 years after symptom onset (Testa 
et al., 2004; Turner et al., 2003).  
Older age at symptom onset is strongly associated with poor survival (del Aguila et al., 
2003). Survival is longer and may exceed 10 years in patients with symptom onset 
before 40 years of age as compared to onset after 80 years of age where the median 
survival is less than two years (Pradas et al., 2013; Testa et al., 2004).  
Other poor prognostic indicators include bulbar onset disease, early respiratory 
dysfunction, rapid progression of symptoms with decline in the ALSFRS-R scores and 
short time from symptom onset to diagnosis (Chio et al., 2009a; del Aguila et al., 2003). 
Malnutrition is an independent prognostic factor for survival in patients with an 
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approximate eight fold increased risk of death (Desport et al., 1999; Marin et al., 2011). 
Certain phenotypes for instance flail limb variant and PLS tend to have a better 
prognosis (Wijesekera et al., 2009). 
 
1.14 Quality of life (QOL) in Motor Neurone Disease 
The term ‘quality of life’ is commonly used in all spheres of life but is conceptually an 
ill-defined term, because of the lack of a universally accepted definition (Rapley, 2003). 
QOL is a widely used term, but with little consistency and means different things to 
different people, depending on the context and area of application (Fayers and Machin, 
2007). The World Health Organisation (1995) defines QOL as a subjective, multi-
dimensional concept that is embedded in the cultural, social and environmental context 
and embraces both positive and negative facets of life.   
The term ‘health related quality of life’ is frequently used to differentiate between 
global QOL in general terms and QOL related to health in clinical medicine and clinical 
trials (Fayers and Machin, 2007). Health related QOL is also a difficult and multifaceted 
concept with a number of dimensions which includes physical, social, psychological, 
cognitive, sexual and spiritual issues (Fayers and Machin, 2007; Haas, 1999). The aim 
of health related QOL measurement is to quantitatively evaluate the impact of the 
illness as well as treatment on an individual, as different patients respond differently, 
both to illness and to treatment (Guyatt et al., 1993). 
QOL is remarkably preserved during the course of illness in majority of patients with 
MND despite decline in strength and function (Robbins et al., 2001).  This may be 
because QOL in MND does not seem to correlate with physical functioning and strength 
but appears to depend on psychological, spiritual, religious and support factors (Robbins 
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et al., 2001; Simmons et al., 2000). Increasing hopelessness, fatigue, loss of speech, 
impaired respiratory function and depression are associated with poor QOL (Bourke et 
al., 2001; Bromberg, 2007; Lou et al., 2003). Strong social support and spirituality are 
positively associated with perceived good QOL among MND patients (Bromberg, 2007; 
Walsh et al., 2003).  
The importance of QOL as a major outcome variable has become increasingly obvious 
in the management of MND (Clarke et al., 2001). In the absence of a cure, management 
is mainly supportive and palliative, focussed on preserving independence and QOL 
(Andersen et al., 2012). Measuring and monitoring QOL is therefore important in 
assessing the effectiveness of any supportive treatment (Brooks, 1997; Neudert et al., 
2004). The consensus guidelines for the design and implementation of clinical trials in 
MND also recommend that a QOL assessment should be developed and incorporated 
into every clinical trial (Miller et al., 1999). 
 
1.14.1 Instruments for assessment of quality of life 
A number of instruments have been used for assessment of QOL in MND. However, 
there is lack of consensus on which instrument is most appropriate for measuring QOL 
(Epton et al., 2009; Simmons et al., 2000). An ideal QOL measurement tool should 
produce the same results on repeated trials (reliability), appear to measure what it is 
supposed to measure (face validity), accurately measure the intended theoretical 
construct (construct validity), fully measure the entire scope of the topic being measured 
(content validity), and the results should correlate well with a previously validated 
measure (concurrent validity) (Epton et al., 2009). The instrument should aim to address 
not only the physical but also psychological, spiritual, religious and support factors 
(Robbins et al., 2001; Simmons et al., 2000). 
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Most of the instruments used for assessment of QOL are generic and commonly used 
ones include the sickness impact profile (Bergner et al., 1981), McGill QOL 
questionnaire (Cohen et al., 1995), the 36 item short form health survey (Ware and 
Sherbourne, 1992) and its abbreviated version, the 12 item short form health survey 
(Ware et al., 1996). These scales are health-related and function-based instruments 
which focus on disease progression and daily functioning.  The schedule for the 
evaluation of individual QOL-Direct Weighting (SEIQoL-DW) (Hickey et al., 1996) 
and the Schedule for Meaning in Life Evaluation (SMiLE) (Fegg et al., 2008) are two 
other instruments which capture existential domains of both quality and meaning of life. 
However, these generic instruments are criticised for not assessing features unique to 
MND (Palmieri et al., 2010). Moreover there are limited or insufficient data on their 
validity and reliability (Epton et al., 2009).  
Instruments designed specifically for use in MND include the amyotrophic lateral 
sclerosis assessment questionnaire-40 (ALSAQ-40) (Jenkinson et al., 1999), the 
sickness impact profile/amyotrophic lateral sclerosis-19 (McGuire et al., 1997) and the 
amyotrophic lateral sclerosis specific quality of life instrument - revised (Simmons et 
al., 2006). There are limited data on the reliability and validity of the latter two 
instruments (Epton et al., 2009; Palmieri et al., 2010) .  
The ALSAQ-40 has been demonstrated to show high internal reliability and construct 
and content validity (Jenkinson et al., 1999; Jenkinson et al., 2000; Jenkinson et al., 
2007). However, ALSAQ-40 does not incorporate religious and/or spiritual beliefs 
which are important to many patients (Bremer et al., 2004; Walsh et al., 2003). 
Nonetheless, ALASQ-40 is the most commonly used measurement tool in assessment 
of QOL in MND (Jenkinson et al., 2007; Palmieri et al., 2010). 
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1.15 Management of motor neurone disease 
There is no cure for MND and management strategies are mainly symptomatic and 
supportive, aimed at preservation of QOL and independence (Andersen et al., 2012; 
Bede et al., 2011). Pharmacological treatment options are limited and patients will 
inevitably face major decisions about accepting, deferring or relinquishing life-
sustaining therapies (Ng et al., 2009). Management of MND therefore necessitates 
understanding of the medical, psychosocial and spiritual context of each individual 
patient and family, as these factors will play a role in influencing their decisions 
regarding future care (Bede et al., 2011). 
Symptomatic treatments remain the cornerstone of management and all efforts should 
be made to enhance QOL and help maintain the patient's independence for as long as 
possible (Kiernan et al., 2011; Wijesekera and Leigh, 2009). Patients experience a 
number of symptoms including weakness, cramps, spasticity, dysarthria, dysphagia, 
dyspnoea, excessive salivation, emotional liability, insomnia, fatigue, anxiety and 
depression (Radunovic et al., 2007). Treatment strategies include symptomatic 
management with drugs for instance antidepressants, non-pharmacological approaches 
for instance enteral feeding or a combination of both (Radunovic et al., 2007).  
There is increasing emphasis on delivery of co-ordinated care within a multidisciplinary 
environment where neurologists, MND specialist nurses, physiotherapists, occupational 
therapists, speech and language therapists, dieticians, respiratory physicians, 
gastroenterologists, social workers and  palliative care services work in close 
collaboration (Chio et al., 2006; Ng et al., 2009; Traynor et al., 2003).  The 
understanding that involvement of multidisciplinary team allows timely institution of 
individualised supportive care has led to development of MND clinics and care centres 
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where health care delivery is based on the interdisciplinary care paradigm (Chio et al., 
2006; Ng et al., 2009; Traynor et al., 2003). There is some evidence to suggest that 
multidisciplinary care may improve QOL, possibly due to the delivery of co-ordinated 
care (Ng et al., 2009; Van den Berg et al., 2005). 
In the absence of a cure, supportive care and advance care planning are important 
management strategies and should be discussed with patients and relatives at the earliest 
opportunity (Bede et al., 2011; Ray et al., 2014). There is international consensus on 
ensuring excellence in end of life care as an important focus of management, 
particularly because disability is relentlessly progressive and death generally occurs in a 
predictable fashion (Bede et al., 2011; Mitsumoto et al., 2005).  
Advance care planning helps to identify and honour care preferences of patients (Bede 
et al., 2011; Chhetri et al., 2015; Mitsumoto et al., 2005). In addition, advance care 
planning also empowers patients to gain control over their end of life care and enables 
them to die at their preferred place of death (Chhetri et al., 2015; Ray et al., 2014). 
Advance care planning should therefore begin soon after diagnosis and continue 
throughout the disease trajectory as an integral part of holistic care in MND (Bede et al., 
2011; Chhetri et al., 2015; Ray et al., 2014).  
 
1.15.1 Disease modifying therapy 
Riluzole, an inhibitor of glutamate release, is the only disease modifying therapy 
licensed for use in MND. Glutamate is an excitatory neurotransmitter in the central 
nervous system that accumulates in toxic concentrations at synapses and causes death of 
motor neurones which are susceptible to excitotoxicity (Bensimon et al., 1994; 
Rothstein, 2009).  Riluzole presynaptically inhibits the release of excitotoxic glutamate 
and also blocks some of the postsynaptic effects of glutamate (Bensimon et al., 1994). 
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Two large randomised controlled trials have demonstrated that use of riluzole extends 
survival by 3 to 6 months (Bensimon et al., 1994; Lacomblez et al., 1996).  However, 
only patients with ALS participated in these trials and the therapeutic benefit of riluzole 
in other MND phenotypes remains unknown.   
 
1.15.2 Respiratory management 
Neuromuscular respiratory insufficiency leading to respiratory failure is a common 
cause of death (Radunovic et al., 2007). A high index of suspicion is required to identify 
early respiratory involvement (Gautier et al., 2010). Assessment of respiratory function 
includes overnight pulse oximetry, early morning arterial blood gas analysis and 
pulmonary function tests, particularly forced vital capacity (Miller et al., 2009).  
Non-invasive ventilation (NIV) has been demonstrated to improve survival and QOL 
(Bourke et al., 2006; Radunovic et al., 2007). In a randomised trial of NIV in 41 
participants, there was an average increase in survival of 48 days among ventilated 
patients (Bourke et al., 2006). The survival advantage was much greater (205 days) in 
patients with normal or only moderately impaired bulbar function. No survival benefit 
was seen in patients with poor bulbar function but NIV significantly improved sleep 
related symptoms (Bourke et al., 2006).  
The randomised controlled trial also demonstrated an improved QOL in addition to 
survival benefit (Bourke et al., 2006). QOL was measured by using the short form 36 
and the symptoms domain of the sleep apnoea quality-of-life index. The QOL in the 
NIV group was maintained above 75% of baseline during the study period and the QOL 
benefits exceeded the improvement in survival. The authors concluded that NIV 
improved survival and QOL rather than prolonging suffering (Bourke et al., 2006).  
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Practice guidelines recommend that NIV should be considered to treat respiratory 
insufficiency in MND (Andersen et al., 2012; Miller et al., 2009). There has been a 
sustained improvement in respiratory management of patients with MND and 
domiciliary provision of NIV has become an important facet of symptomatic 
management in MND (Kiernan et al., 2011; Wijesekera et al., 2009).   
 
1.15.3 Nutritional management  
Malnutrition is an independent prognostic factor for survival in MND with an eight fold 
increased risk of death (Desport et al., 1999; Marin et al., 2011).  MND is associated 
with altered nutritional state, energy intake and energy expenditure. Nutritional state has 
prognostic value for survival at various stages of the illness: at the time of diagnosis 
(Marin et al., 2011), at the time of gastrostomy placement (Desport et al., 2000) or 
during the course of the disease (Stambler et al., 1998).  
Weight loss from baseline of 5% or more at the time of diagnosis is associated with a 
twofold increased risk of death (Marin et al., 2011). Body mass index of less than 18.5 
kg/m
2
 at the time of gastrostomy placement is an unfavourable prognostic factor 
(Desport et al., 2000). Malnutrition and weight loss is a frequent phenomenon in MND 
and occurs in approximately 55% of patients with the condition (Mazzini et al., 1995). 
Patients may not be able to meet their nutritional needs for a number of reasons 
including motor weakness interfering with self-feeding and meal preparation, reduced 
caloric intake, dysphagia, anxiety, depression, respiratory insufficiency and  
hypermetabolism (Bouteloup et al., 2009; Desport et al., 2000; Greenwood, 2013; 
Heffernan et al., 2004). Hand weakness slows eating and makes patients dependent on 
others for preparing meals and in feeding the patients (Radunovic et al., 2007). 
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Weakness of the tongue and pharyngeal muscles impair swallowing (Simmons, 2005). 
Anxiety and depression can lead to anorexia (Radunovic et al., 2007).   
The energy intakes are below recommended dietary allowances in more than 70% of 
patients (Genton et al., 2011).  Hypermetabolism resulting from a number of factors 
including include greater effort of breathing, muscle fasciculations and frequent 
infections, for instance, aspiration pneumonia leads to increased resting energy 
expenditure (Bouteloup et al., 2009).   
Bulbar muscles involved in speech and swallowing are initially involved in 25% of 
patients with MND, but eventually majority of patients experience bulbar involvement. 
There is progressive difficulty in swallowing leading to aspiration pneumonia, 
distressing choking, prolonged effortful meal times, weight loss, malnutrition and/or 
dehydration (Heffernan et al., 2004; Simmons, 2005). Malnutrition further aggravates 
muscle weakness and respiratory function (Greenwood, 2013). Nutritional insufficiency 
may evolve gradually and asymptomatically, and therefore, a proactive approach for 
early recognition and intervention may delay the attendant complications (Kasarskis et 
al., 2011). 
Nutritional assessment is recommended on a three monthly basis through measurement 
of body weight (Miller et al., 2009). The various strategies to maintain appropriate 
caloric intake include use of nutritional supplements for instance high protein and 
caloric diets, adjustments in diet consistency and the use of feeding techniques, such as 
chin tuck and taking small meals (Andersen et al., 2012; Hardiman, 2000; Heffernan et 
al., 2004). With inevitable disease progression, these measures become insufficient and 
enteral feeding may be needed (Greenwood, 2013; Miller et al., 2009).  
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1.16 Enteral feeding in motor neurone disease   
Enteral feeding refers to delivery of any form of nutrition through a tube which may 
include nasogastric, gastrostomy or jejunostomy tube placed in the upper 
gastrointestinal tract (Kirby et al., 1995; Koretz et al., 2007).  The American Academy 
of Neurologists (AAN) and European Federation of Neurological Societies (EFNS) 
recommend enteral feeding in MND (Andersen et al., 2012; Miller et al., 2009). 
However, there is a lack of consensus on the appropriate timing of feeding tube 
insertion (Katzberg and Benatar, 2011).  
Practice guidelines state that enteral nutrition should be considered in patients with 
dysphagia and/or decline in nutritional state (as indicated by weight loss of more than 
10% from pre-morbid weight or body mass index of less than 18.5 kg/m
2
) and while 
forced vital capacity is more than 50% of predicted value (Andersen et al., 2012; 
Desport et al., 2000; Miller et al., 2009). The common methods of delivering enteral 
nutrition in MND includes use of nasogastric tube, percutaneous endoscopic 
gastrostomy (PEG) tube (Figure 1.12) or radiologically inserted gastrostomy (RIG) tube 
(Katzberg and Benatar, 2011; Miller et al., 2009).  
Nasogastric tube feeding offers a short term feeding measure, but the evidence for long 
term nutritional support is not as favourable as gastrostomy tube feeding due to high 
risk of aspiration pneumonia and inconveniences, particularly in patients with increased 
oropharyngeal secretions, drooling and choking (Heffernan et al., 2004; Scott and 
Austin, 1994). 
Percutaneous endoscopic gastrostomy tube feeding is the most commonly used method 
for long term nutritional maintenance in MND (Heffernan et al., 2004; Silani, 1998).  
PEG tube insertion is a commonly performed procedure by a trained endoscopist under 
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conscious sedation. Risks of the procedure include pain, aspiration pneumonia, 
respiratory arrest, laryngeal spasm, localized infection, bowel perforation, gastric 
haemorrhage and placement failure due to technical difficulties (Mazzini et al., 1995; 
Thornton et al., 2002).  
The morbidity and mortality rates associated with PEG placement increases when a 
patient has significant respiratory impairment as indicated by a forced vital capacity of 
less than 50% (Kasarskis et al., 1999; Mazzini et al., 1995). Under these circumstances 
RIG may be safer than PEG (Blondet et al., 2010; Chio et al., 2004).  
 
 
 
Figure 1.12: Photograph showing percutaneous endoscopic gastrostomy tube in situ 
(printed with patient’s consent) 
RIG is performed under fluoroscopic guidance through percutaneous access and does 
not need endoscopy or conscious sedation, thereby reducing the risks of respiratory 
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insufficiency (Chio et al., 2004). However, there is increased risk of tube obstruction as 
the tube is of smaller diameter than the PEG tube (Chio et al., 2004).  Only few studies 
have compared RIG with PEG (Allen et al., 2013; Blondet et al., 2010). RIG therefore 
needs further validation in the MND cohort through prospective randomized studies 
(Allen et al., 2013; Blondet et al., 2010). 
A relatively new hybrid gastrostomy technique, per-oral image-guided gastrostomy 
(PIG) has been developed as an effective alternative method of gastrostomy insertion 
with a higher success and lower re-intervention and complication rates (Laasch et al., 
2003). In this procedure, the stomach is punctured under fluoroscopic guidance and the 
oesophagus is catheterised in a retrograde technique with the aid of a guide wire. The 
gastrostomy tube is then fed over the guide wire, through the mouth into the oesophagus 
and finally brought out through the abdominal wall (Laasch et al., 2003). 
PIG combines the advantages of both PEG and RIG while minimising their 
disadvantages (Laasch et al., 2003). It is performed under minimal conscious sedation 
or local anaesthesia and obviates the need for endoscopic intubation (Chavada et al., 
2010; Laasch et al., 2003). A large bore feeding tube can be used and this reduces the 
risk of tube blockage and migration (Chavada et al., 2010; Stavroulakis et al., 2013). 
Preliminary evidence suggests that PIG could be a safe, well tolerated and reliable 
alternative method for gastrostomy insertion in MND (Chavada et al., 2010).  
 
1.17 Working hypothesis 
Enteral feeding improves QOL of patients with MND through management of 
dysphagia and/or malnutrition.  
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1.18 Main Aim of the study 
The main aim of the study was to assess the impact of enteral feeding on survival, 
nutritional status and QOL of patients with MND.  
 
1.19 Objectives of the study  
1. To undertake a systematic literature review regarding the impact of enteral 
feeding on survival, nutritional status and QOL of patients with MND.  
2. To investigate epidemiology, demographics, clinical and survival characteristics 
of MND in Lancashire and South Cumbria in North West England through an 
eight year retrospective review of the Preston MND database and patient case 
notes. 
3. To evaluate the impact of enteral feeding on survival through an eight year 
retrospective review of Preston MND database and patient case notes. 
4. To examine change in nutritional status through measurement of body mass 
index at the time of diagnosis, gastrostomy insertion, and 3, 6 and 12 months 
following enteral feeding. 
5. To explore patients’ perspectives about enteral feeding and its impact on their 
quality of life through a thematic analysis of their experiences with enteral 
feeding. 
6. To analyse the data and write up the MD thesis.  
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CHAPTER 2 
 
 
 
OUTCOMES OF ENTERAL 
NUTRITION: 
A SYSTEMATIC REVIEW 
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2.1 Introduction 
This chapter presents a systematic review undertaken to identify and to analyse results 
from research studies on the impact of enteral feeding on survival, nutritional status and 
QOL in patients with MND. A systematic review aims to answer a defined research 
question by systematically identifying, appraising and synthesising all relevant high 
quality research evidence that fits the pre-specified eligibility criteria (Akobeng, 2005; 
Cook et al., 1997).  
The use of explicit and reproducible methods in undertaking a systematic review limits 
bias, generates reliable conclusions and allows comparison of a number of studies to 
establish consistency and generalisability of findings (Akobeng, 2005; Cook et al., 
1997). Systematic reviews may identify areas that lack adequate evidence and/or areas 
where further research is needed (Cook et al., 1997; Greenhalgh, 1997).  
A preliminary, non-systematic literature search did not identify any randomised 
controlled trials of enteral feeding in MND.  However, without a comprehensive and 
meticulous search, it would be inappropriate to conclude that none have been 
undertaken. A systematic review has therefore been undertaken in this thesis to 
ascertain the best available evidence on the impact of enteral feeding on survival, 
nutritional status and QOL of patients with MND. The systematic review was also 
intended to identify areas of research that would subsequently become the focus of this 
thesis.  
 
2.2 Aim of systematic review 
The main aim of systematic review was to systematically identify and review research 
studies on enteral feeding and their outcomes in patients with MND.  
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2.3 Objectives of systematic review  
The three main objectives of the systematic review were to systematically identify and 
review results of research studies investigating the impact of enteral feeding on: 
1. Quality of life  
2. Nutritional status  
3. Survival 
 
2.4 Methodology 
2.4.1 Inclusion criteria 
Types of studies  
All studies including randomised controlled trials, quasi-randomised trials, prospective 
and retrospective studies investigating the effectiveness of enteral feeding in MND were 
reviewed.  
Target population  
Patients diagnosed with definite, possible, or probable MND according to the El 
Escorial criteria (Brooks, 1994) or revised El Escorial criteria (Brooks et al., 2000) that 
had undergone feeding tube insertion were included in the review.   
Types of Intervention  
The review looked into all studies, both retrospective and prospective, that reported 
placement of any form of feeding tube including nasogastric, gastrostomy or 
jejunostomy tubes during the course of the illness.  
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2.4.2 Exclusion Criteria 
Articles published in languages other than English were excluded, as there were no 
resources for translation of these articles. Studies that were only published as abstracts 
were excluded because of the limited data that could be extracted.  
 
2.5 Outcome measures  
Primary outcome measure  
The primary outcome was self-perceived quality of life assessed with or without quality 
of life scale.  
Secondary outcome measures 
The secondary outcomes were: 
1. Survival time either from symptom onset, time of diagnosis or feeding tube 
placement. 
2. Change in nutritional status measured by body weight or body mass index.  
 
2.6 Search Strategy 
A search strategy was developed to search MEDLINE from 1966 to July 2014, and 
adapted to search EMBASE for all studies reporting enteral feeding in  MND using 
‘amyotrophic lateral sclerosis’, ‘motor neurone disease’, ‘motor neuron disease’, ‘Lou 
Gehrig’, ‘gastrostomy’, ’percutaneous endoscopic gastrostomy’, ‘PEG’ ‘enteral 
feeding’, ‘enteral nutrition’, ‘nasogastric feeding’, ‘radiologically inserted gastrostomy’, 
‘RIG’, and ‘feeding tube’, as search terms.  
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Citations were initially screened on title and those retained were screened on abstract. 
This was carried out independently by the author. If the information was inadequate to 
decide whether the article should be included in the review, the full paper was obtained. 
Any published article that appeared to meet the inclusion criteria was read in full. The 
published articles were also checked to identify any further articles of relevance. The 
MEDLINE and EMBASE search strategies are outlined in Appendix 1 and 2. 
 
2.7 Data collection and analysis 
The data from identified studies were extracted into a word document (Table 2.1). For 
each article included in the review, summary data were recorded including author, year 
of publication, type of study, number of patients in each group (enteral feeding versus 
no enteral feeding), QOL benefit from enteral feeding, nutritional benefit from enteral 
feeding, survival benefit from enteral feeding and control for potential confounders 
including onset site and riluzole use. The results are presented narratively because the 
published studies were heterogeneous in terms of their methodologies, outcome 
measures and confounders.  
 
2.8 Results 
The literature search identified a total of 615 articles and from these, 309 duplicates 
were removed. Following screening of the title, abstract or complete article, 19 
remaining studies met the inclusion criteria. There were no randomized or quasi-
randomised controlled trials. 4 studies were prospective and the remaining retrospective 
in nature. Figure 2.1 outlines the results of the search.  The studies meeting the 
inclusion criteria are summarised in table 2.1.  
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Figure 2.1: Flow diagram showing the summary of methodology for the systematic 
review of outcomes of enteral feeding in MND.  
Total number of publications 
identified (N = 615) 
 
 
 
Duplicates excluded (N = 309) 
Publications identified for screening 
(N = 306) 
Papers excluded on basis of 
title and abstract (N= 272) 
Papers retrieved for more detailed 
evaluation (N = 34) 
Papers excluded on reading 
full paper (N = 15) 
Final papers included in the review 
(N = 19) 
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Table 2.1: Table showing the summary of studies included in the systematic review 
 
Author Year 
 
Study type 
 
No of patients 
 
Quality of 
life benefit 
 
Nutritional 
benefit 
 
Survival 
benefit 
    
 
Mathus-
Vliegen et al. 
(1994) 
 
Prospective 
cohort 
 
55 gastrostomy 
vs 13 oral 
feeding/ 
nasogastric 
feeding 
 
 
Not 
reported 
 
Not 
reported 
 
No  
 
Mazzini et 
al. (1995) 
 
Prospective 
cohort 
 
31 gastrostomy 
vs 35 oral 
feeding 
 
Anecdotal 
benefit 
only 
 
 
Yes 
 
Yes 
 
Strong et al. 
(1999) 
 
Case control  
 
73 gastro-
jejunostomy  vs 
293 oral feeding 
 
 
Not 
reported 
 
Not 
reported 
 
No 
 
Chio et al. 
(1999) 
 
Case control 
 
50 gastrostomy  
vs 100 oral 
feeding 
 
Not 
reported 
 
Yes but 
observati-
onal only 
 
 
Yes 
 
Kasarskis  
et al. (1999) 
 
Retrospective 
cohort 
 
172 gastrostomy 
 
Not 
reported 
 
Yes but 
observati-
onal only 
 
 
Not 
reported 
 
Desport et al. 
(2000) 
 
Case control 
 
30 gastrostomy  
vs 30 oral 
feeding 
 
 
Not 
reported 
 
Yes 
 
No 
 
Mitsumoto  
et al. (2003) 
 
Case control  
 
137 gastrostomy  
vs 187 oral 
feeding 
 
17% 
improved 
mental 
wellbeing  
 
 
Yes but 
observati-
onal only 
 
No 
 
Forbes et al. 
(2004) 
 
Case control 
 
142 gastrostomy 
vs 
1084 oral 
feeding 
 
 
Not 
reported 
 
Not 
reported 
 
No 
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Chio et al. 
(2006) 
 
Prospective 
cohort 
 
52 gastrostomy 
vs 169 oral 
feeding  
 
 
Not 
reported 
 
Not 
reported 
 
Yes 
 
Czaplinski et 
al. (2006) 
 
Case control  
 
275 gastrostomy  
vs 766 oral 
feeding 
 
Not 
reported 
 
 
Not 
reported 
 
Yes 
 
Mitchell et 
al. (2006) 
 
Case control 
 
127 gastrostomy 
versus 348 oral 
feeding  
 
 
Not 
reported 
 
Not 
reported 
 
No 
 
Sorenson et 
al. (2007) 
 
Case control 
 
12 gastrostomy 
vs 28 oral 
feeding 
 
Not 
reported 
 
Not 
reported 
 
No 
 
Murphy et al. 
(2008) 
 
Prospective 
cohort 
 
57 gastrostomy 
vs 187 oral 
feeding 
 
Not 
reported 
 
 
Not 
reported 
 
No 
 
Lou et al. 
(2010) 
 
Retrospective 
cohort 
 
52 gastrostomy 
 
Yes 
 
Not 
reported 
 
Not 
reported 
 
 
Spataro et al. 
(2011) 
 
Case control  
 
76 gastrostomy 
vs  74 oral 
feeding 
 
Not 
reported 
 
 
Not 
reported 
 
Yes  
 
Atassi et al. 
(2011) 
 
Case control 
 
38 gastrostomy 
vs 262 oral 
feeding 
 
Not 
reported 
 
 
Not 
reported 
 
No 
 
Zamietra et 
al. (2012) 
 
Case control 
 
11 gastrostomy 
vs 6 ventilation 
and 5 
gastrostomy and 
ventilation 
 
 
No 
 
Not 
reported  
 
Not 
reported 
 
Zhang et al. 
(2012) 
 
Case control 
 
31 gastrostomy 
vs 35 oral 
feeding 
 
Not 
reported  
 
Yes, 
observati-
onal only  
 
 
No 
 
Georgoulopo
ulou et al. 
(2013) 
 
Case control 
 
95 gastrostomy 
vs 
98 oral feeding 
 
Not 
reported 
 
Not 
reported 
 
No 
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2.9 Measurement scales used in the identified studies 
A number of measurement scales were used for evaluation of QOL. The following 
scales were used in the identified studies:  
 
Short Form-12 health survey 
The Short Form-12 (SF-12) health survey consists of 12 questions designed to rate a 
number of aspects of a patient’s mental and physical functioning (Ware et al., 1996). 
The questionnaire is self-administered and involves the patient responding, for the most 
part, on ‘Likert’-type response scales although there are some simple ‘yes/no’ responses 
on some domains (Ware et al., 1996). 
 
Mini-Sickness Impact Profile  
The Mini-Sickness Impact Profile consists of a subset of 19 yes or no questions from 
the Sickness Impact Profile (SIP), which is a general functional status instrument 
comprising 136 items (Bergner et al., 1981; McGuire et al., 1997). The questions 
encompass physical, psychological and social domains of QOL.  
 
Single Item McGill Quality of Life Scale  
The Single Item McGill Quality of Life Scale (MQOL-SIS) is an item in the McGill 
Quality of Life (MQOL) questionnaire asking subjects to rate their overall QOL on a 
scale from 0 (very bad) to 10 (excellent).  The MQOL questionnaire has 16 other 
questions divided into five domains: physical symptoms, physical well-being, 
psychological, existential, and support (Cohen et al., 1995; Cohen et al., 1996). Each 
question is rated from 0 (very bad) to 10 (excellent). 
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Amyotrophic Lateral Sclerosis Specific Quality of Life Instrument - Revised  
The Amyotrophic Lateral Sclerosis Specific Quality of Life Instrument-Revised 
(ALSSQOL-R) is a 50-item ALS specific QOL instrument that is completed by an 
individual with MND (Simmons et al., 2006). Each item is rated by the individual using 
a 0 to 10 point Likert scale, with 0 being the least desirable situation and 10 being the 
most desirable situation in six different domains:  negative emotion; interaction with 
people and the environment; intimacy; religiosity; physical symptoms and bulbar 
function. 
 
Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised  
The Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) is a 
validated 12 item scale that measures bulbar function, upper extremity function, lower 
extremity function and respiration in patients with MND (Cedarbaum et al., 1999).  
Each item is scored from 0 (poorest function) to 4 (normal function) and the scores are 
added to generate a total score from 0 (worst function) to 48 (normal function). The 
bulbar subscale consists of the domains of swallowing, speech and salivation with each 
item rated from 0 which indicates marked dysfunction to 4 which implies normal 
function.     
The ALSFRS-R is widely used for evaluation of functional and clinical status of MND 
patients (Kollewe et al., 2008).  The questionnaire is easy to administer, sensitive and 
clinically meaningful and can be completed by the patient or caregiver or administered 
by the clinician or a trained evaluator (Gordon et al., 2004; Miano et al., 2004).  
The scale is patient rather than clinician centered and measurements are therefore 
undertaken from a patient’s perspective (Kaufmann et al., 2005). It is also a cost 
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effective way of measuring functional status as it does not require any special 
equipment unlike other measures like muscle strength testing (Gordon et al., 2004).  
The scale is reliable and reproducible with a number of favourable properties including 
high internal consistency, test-retest reliability and construct validity (Cedarbaum et al., 
1999; Gordon et al., 2004). It also has excellent inter-rater and intra-rater reliability 
(Kaufmann et al., 2007; Miano et al., 2004). There is high consistency and the change in 
scores over time closely parallels change in other measures, including muscle strength 
testing and forced vital capacity (Brooks et al., 1996; Cedarbaum and Stambler, 1997).   
The scale has been validated for administration over the telephone and internet and 
highly correlates with in-clinic administration (Kasarskis et al., 2005; Maier et al., 
2012). The assessment can also be completed by communicating with the 
spouse/caregiver over the phone. This provides flexibility as it can be administered to 
patients who are unable to attend the clinic (Kasarskis et al., 2005; Maier et al., 2012). 
The instrument has also been validated for self-administration (Montes et al., 2006). 
The ALSFRS-R scores can also be accurately reproduced from information in clinic 
notes and therefore, is a useful research tool in retrospective studies (Lechtzin et al., 
2009). 
The ALSFRS-R also predicts survival outcomes in both clinic and trial settings (Kimura 
et al., 2006). Baseline ALSFRS-R scores are predictive of survival time in both clinical 
trial and clinic settings with higher scores indicative of a worse prognosis (Cedarbaum 
et al., 1999; Kaufmann et al., 2005). The ALSFRS-R scores also predict length of 
hospital stay and survival of patients on mechanical ventilation (Lo Coco et al., 2007).  
The ALSFRS-R, however, has few limitations. The ALSFRS-R may not accurately 
reflect changes in QOL which may be may be maintained despite deterioration in 
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physical function (Robbins et al., 2001). Finally, the scale does not include items to 
assess cognitive function which may occur in more than 40% of patients with MND 
(Phukan et al., 2012). Despite these limitations, ALSFRS-R has a number of favourable 
properties and is a widely used tool in both clinical and research settings (Gordon et al., 
2004; Kollewe et al., 2008). 
 
 The Norris scale  
The Norris scale is a 100 point clinical and functional rating scale for assessing disease 
progression in MND and consists of 22 items in various domains including the bulbar, 
limb and respiratory functions (Norris Jr et al., 1974). 
 
2.10 Quality of life outcomes of enteral nutrition 
The systematic review identified only four studies reporting changes in self-perceived 
QOL after enteral nutrition, of which only one was prospective (Mazzini et al., 1995) 
and the remaining retrospective in nature (Lou et al., 2010; Mitsumoto et al., 2003; 
Zamietra et al., 2012).  
In a prospective cohort study of 31 MND patients undergoing gastrostomy insertion, 
Mazzini et al. (1995) reported anecdotal impressions from patients about their improved 
QOL following gastrostomy feeding. The patients were interviewed by a Psychologist 
on a three monthly basis over a two year period to assess their QOL. However, the 
authors do not convey any concrete data relating to their observations.  
Mitsumoto et al. (2003) compared QOL of 137 patients who had received enteral 
feeding versus 187 patients who continued to feed orally. This was a retrospective study 
aimed at evaluating clinical characteristics of MND patients with and without 
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gastrostomy. A cut off score of ≤ 5 on the bulbar subscale of the ALSFRS was used to 
select the cases and controls. Health status of the patients had been recorded using the 
generic SF -12 health survey and the mini-sickness impact profile.  
Only 17% of the patients reported improved psychological wellbeing and 28% reported 
less fatigue or less time spent on meals and medications (Mitsumoto et al., 2003). The 
physical and mental domains of the SF-12 health status scale were similar in both 
groups. Patients with gastrostomy feeding experienced poorer health status (p=0.0047) 
on the mini-sickness impact profile scale as compared to those who continued to feed 
orally. However, the bulbar sub scores were significantly lower (p<0.0001) in the 
gastrostomy group indicating that gastrostomy was performed too late to demonstrate a 
positive impact on QOL (Mitsumoto et al., 2003).  
Lou et al. (2010) undertook a retrospective study to investigate the correlates of QOL 
including enteral feeding in patients who participated in the minocycline trial. This was 
a double-blinded, placebo-controlled drug trial of 412 subjects aimed at assessing the 
efficacy of minocycline as a treatment for MND. QOL was evaluated using the MQOL-
SIS.  A total of 52 patients received PEG feeding during the trial and the authors 
compared the slopes of MQOL-SIS before and after PEG tube insertion. In each of the 
study subjects, at least three data points before and after PEG placement was obtained. 
The authors reported a statistically significant reduction (p<0.001) in the rate of decline 
on the MQOL-SIS, suggesting that PEG feeding improves QOL.  
Zamietra et al. (2012) retrospectively reviewed 11 patients who had received PEG 
feeding. They compared the PEG group to a cohort of 6 patients who had received non-
invasive positive pressure ventilation and another cohort of 5 patients who had received 
both PEG feeding and non-invasive positive pressure ventilation. The overall QOL had 
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been measured using the ALSSQOL-R. The QOL assessments had been obtained at the 
last routine clinic visit prior to intervention and for two consecutive visits following 
gastrostomy insertion, usually on a three monthly basis. ALSSQOL-R was relatively 
stable over time in all three groups. Although the QOL in the gastrostomy group 
deteriorated marginally over time, the difference was not statistically significant. 
However, this is a small observational study lacking a control group and the patients 
were not specifically asked about the impact of enteral feeding on their QOL.  
 
2.11 Nutritional outcomes of enteral feeding 
A total of 6 studies reported nutritional outcomes in association with enteral feeding. In 
a prospective study, Mazzini et al. (1995)  reported statistically significant improvement 
in nutritional status of 31 patients undergoing enteral feeding as compared to a control 
group of 35 patients who refused gastrostomy. Gastrostomy placement was proposed to 
69 cases with mild or severe dysphagia and weight loss of more than 5% of their normal 
body weight. The procedure was unsuccessful in three patients who had difficulty in 
opening their mouth because of spasticity. The average weight gain after a year of 
enteral feeding was 2.5 kilograms. Following enteral feeding, the BMI increased by 0.5 
points over a period of 12 months as compared to a decrease of 4.5 points in the group 
who continued to feed orally.  
In a case control study aimed at investigating the safety and factors related to survival 
after PEG, Chio et al. (1999) matched 50 MND patients undergoing gastrostomy 
feeding with 100 historical controls without gastrostomy for age at diagnosis, site of 
onset and severity of disease as indicated by the forced vital capacity and Norris score at 
diagnosis. 35 patients with enteral feeding survived more than 90 days, of which 71% 
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gained weight (from 5.3 to 9.6%) with weight stabilisation in the remainder. However, 
no comparison was made with the control group in terms of change in nutritional status. 
Kasarskis et al. (1999) performed a retrospective analysis of MND patients participating 
in clinical trials to determine their clinical profile at the time of gastrostomy and define 
prognostic factors for early mortality following gastrostomy placement. A total of 136 
patients in the Brain Derived Neurotrophic Factor (BDNF) study and 36 placebo 
patients in the Ciliary Neurotrophic Factor (CNTF) study received gastrostomy feeding 
during the study period. Patients were evaluated on a monthly basis for nine months in 
both studies. BMI was recorded in each visit. Two pre-gastrostomy and two post-
gastrostomy visits were undertaken to assess trends in BMI. A significant stabilization 
(p=0.0001) in BMI was noted following enteral feeding. This was however an 
observational study, as the clinical trials were not designed to assess the nutritional 
benefit of enteral feeding.  
In a retrospective study comparing 30 patients who underwent enteral feeding with 30 
patients who did not receive enteral nutrition, Desport et al. (2000) reported a 
significant nutritional advantage in the patients undergoing gastrostomy insertion. A 
significant weight gain of 8% (p<0.02) was noted in the cohort receiving enteral 
feeding. However, the authors do not report the clinical characteristics of the control 
group. It is also unclear whether the patients in the control group refused gastrostomy or 
had no indications to necessitate enteral feeding. 
Mitsumoto et al. (2003) reported an average weight gain of 2.9 kilograms in 137 
patients with enteral feeding. The patients were identified from the American ALS 
patient care database. This was, however, an observational finding and the change in 
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nutritional status was not compared with the control group of 187 patients who 
continued to feed orally. 
Zhang et al. (2012) reported weight stabilisation at 3 and 6 months in 31 patients 
receiving enteral feeding as compared to 35 patients without enteral feeding. The BMI 
was 22.6 ± 2.2 kg/m
2
 at 3 months and 22.5 ± 2.0 kg/m
2
 at 6 months following 
gastrostomy as compared to a BMI of 22.5 ± 3.0 kg/m
2
 at the time of gastrostomy 
placement. However this was not sustained and weight loss recurred in the terminal 
stages of the illness.  
 
2.12 Survival outcomes of enteral feeding 
A number of studies reporting survival outcomes of enteral feeding in MND were 
identified.  Some of these studies were prospective and others retrospective in nature. 
However, none of these studies were primarily designed to assess the impact of enteral 
feeding on survival.  
Mathus-Vliegen et al. (1994) prospectively investigated the use of PEG in 68 MND 
patients with impaired pulmonary function. Patients were required to have adequate 
pulmonary function as indicated by a FVC of 1 litre or more to be considered for PEG. 
A total of 55 patients received PEG while 13 patients were considered ineligible due to 
impaired pulmonary function.  There was no significant survival advantage with PEG 
feeding. Median survival from symptom onset in the PEG group was 31.8 months as 
compared to 29.6 months in the group not eligible for PEG. However, 6 of the 13 
ineligible patients underwent nasogastric feeding and this introduces a bias in assessing 
the survival benefit of enteral feeding. The absence of any survival advantage is 
therefore questionable because of this methodological bias.  
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Mazzini et al. (1995) prospectively compared survival of 31 patients undergoing PEG 
feeding with 35 control patients. PEG was offered to patients with mild or severe 
dysphagia and weight loss of more than 5% of their usual body weight. The control 
group had refused PEG. Significant survival advantage was noted with enteral feeding 
(p<0.03). Patients in the PEG cohort had a mean survival of 38 months from symptom 
onset as compared to 30 months for the control group. There was no significant 
difference in mortality between the two groups for the first 6 months but  a notable 
difference was observed at 12 months (p<0.05) and 24 months (p<0.001) post 
gastrostomy. It is unclear whether the illness was of limb or bulbar onset in both the 
groups. Patients with limb onset illness have a better prognosis (Chio et al., 2009a; del 
Aguila et al., 2003), and the lack of matching in this study introduces a potential bias.   
Chio et al. (1999) investigated survival in a case control study of 50 patients with and 
without PEG feeding. The PEG group were matched with 100 historical controls 
without gastrostomy. The median survival time after PEG feeding was 185 days. The 
median survival time from diagnosis in the PEG cohort was 915 days as compared to 
760 days in the control group. Multivariable analysis demonstrated significant survival 
advantage both in the whole PEG cohort and bulbar onset patients, but not in spinal 
onset patients. The cohort without PEG had a hazard ratio of 1.55 (95% CI 1.28-1.88, p 
=0.02). Bulbar onset patients not receiving enteral feeding had a hazard ratio of 1.83 
(95% CI 1.39-2.40, p=0.02).  
Strong et al. (1999) undertook a retrospective review of percutaneous gastro-
jejunostomy feeding in MND. Survival of 73 patients with enteral feeding was 
compared against 293 patients who did not require nutritional support. A negative 
survival advantage was noted with enteral feeding. The median survival in gastro-
jejunostomy group was 22 months for bulbar onset as compared to 30 months in the 
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control group (p<0.001). Similarly, the median survival in the limb onset group was 24 
months with gastro-jejunostomy and 35.5 months in the control group. The survival 
difference in the limb onset group was not statistically significant.  The study subjects 
were, however, not matched with the control group for confounders. Moreover, the 
control group did not require nutritional support indicating that they had a better 
nutritional status as compared to patients requiring enteral feeding. 
In a retrospective study comparing 30 patients who underwent enteral feeding with 30 
patients who did not receive enteral nutrition, Desport et al. (2000) found no survival 
advantage with enteral feeding. However, the authors do not report the clinical 
characteristics of the control group. Moreover, it is unclear whether the patients in the 
control group refused gastrostomy or did not require enteral feeding.  
In a retrospective multi-centre study, Mitsumoto et al. (2003)  compared survival of 137 
patients with PEG feeding against 187 patients with oral feeding. The controls were 
matched for bulbar dysfunction as indicated by a cut-off point of ≤5 in the bulbar 
subscale of ALSFRS. The majority of those who did not receive enteral nutrition had 
refused PEG. No survival advantage was noted with enteral feeding (p=0.33). The 
average survival from symptom onset was 47 months in the PEG group as compared to 
58 months in the control group. However, there was marked variability in the use of 
gastrostomy among participating centres raising the possibility of physician bias in 
recommending enteral feeding.  Moreover, the bulbar sub scores were significantly 
lower in the PEG group (p<0.0001) indicating that gastrostomy was performed too late 
to demonstrate survival benefits.  
Forbes et al. (2004) retrospectively analysed 1226 patients in the Scottish MND 
Register of which 142 had received gastrostomy feeding. The authors found no 
62 
 
evidence of improved survival following enteral feeding. The median survival in the 
gastrostomy group was 759 days as compared to 752 days in the control group. 
However, the two groups were not matched for various confounding factors including 
forced vital capacity and bulbar dysfunction. 
In a retrospective cohort study of  1041 patients of which 275 had undergone 
gastrostomy insertion, Czaplinski et al. (2006) demonstrated significantly improved 
survival with enteral feeding in a multivariate model (hazard ratio 0.75, CI 0.63 to 0.90, 
p=0.003). The authors, however, analysed the median survival from symptom onset 
rather than from the point of gastrostomy. They attributed this limitation to the database 
not being adequate for identifying the timing of gastrostomy placement. The lack of 
survival statistics from the point of gastrostomy makes it difficult to ascertain the true 
impact of enteral feeding on survival.  
Chio et al. (2006) prospectively followed 221 patients over a two year period during 
which 52 patients underwent placement of PEG tube. Patients not receiving gastrostomy 
feeding had a hazard ratio of 3.38 for death as compared to 52 patients with gastrostomy 
(p=0.0006). The indication for PEG feeding has not been defined in the paper. It 
therefore remains unclear whether the clinical characteristics of the PEG cohort were 
similar or different to the group not receiving PEG.  
Mitchell et al. (2006) retrospectively reviewed the records of 625 patients to audit the 
outcomes of use of riluzole in MND. The demographic and survival characteristics of 
475 patients with adequate clinical information were analysed. A total of 127 patients 
had received PEG and 348 continued to feed orally.  No significant survival advantage 
was noted with PEG feeding (hazard ratio=0.59; 95% CI 0.22 to 1.61, p=0.30).  The 
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indications and timing of PEG placement have not been mentioned in the paper. It also 
remains unclear what proportion of the patients with missing data had received PEG.   
In a retrospective study examining the incidence of aspiration pneumonia in 40 patients 
with MND, Sorenson et al. (2007) reported no significant survival difference between 
12 patients with PEG feeding and 28 patients who continued to feed orally. The two 
groups were however not matched for possible confounders. 
In a 22 year prospective study, Murphy et al. (2008) followed 244 patients with definite 
or probable MND. 57 patients underwent PEG insertion. The average time from PEG 
insertion to death was 7.4 months. The median survival from symptom onset for the 
whole cohort was 27.6 months. There was no survival advantage with enteral feeding 
when compared to those who continued to feed orally. However, the groups were not 
matched and the authors have not outlined the indications for gastrostomy.  
In a post-hoc analysis of prospectively collected data from clinical trials of celecoxib 
and coenzyme Q10 in MND,  Atassi et al. (2011) reviewed data of 300 subjects of 
which 38 had received gastrostomy feeding. The authors reported increased mortality 
hazard of 0.28 (p=0.02) in the gastrostomy cohort. The patients were, however, 
followed up for an average of 3.8 months only.  Given the short follow up period, it is 
difficult to ascertain the true impact of enteral feeding as survival advantage is often not 
noticed until 6 months after gastrostomy placement (Mazzini et al., 1995). 
In a retrospective study of 150 patients, Spataro et al. (2011) evaluated the effect of 
PEG feeding on survival of patients with dysphagia. Patients were dichotomised into 
two groups depending on whether they accepted or declined PEG. 76 patients received 
PEG of which 37 had bulbar and 39 limb onset illness. Survival advantage with enteral 
feeding was noted in limb onset cases only with a median survival of 44 months as 
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compared to 36 months without PEG (p=0.046). However, the  diagnostic delay in the 
PEG group was 10.6 ± 8.3 months as compared to 14.8 ± 14 months in the control 
group (p=0.026). It therefore remains unclear whether the reported survival advantage 
was due to enteral feeding or active management as earlier diagnosis and timely access 
to multidisciplinary care is an independent prognostic factor for survival (Chio et al., 
2006; Traynor et al., 2003).   
Enteral feeding was associated with a trend towards longer survival in 31 patents with 
dysphagia as compared to 35 dysphagic patients who either refused the procedure, died 
before PEG placement or were not medically fit for the procedure (Zhang et al., 2012). 
The results were, however, not statistically significant (p=0.089). The findings have 
questionable significance because of methodological bias when comparing survival with 
a group where 9 deaths occurred even before placement of the PEG tube. 
Georgoulopoulou et al. (2013) retrospectively investigated the impact of clinical factors 
and therapeutic interventions on survival of 193 patients with MND. Survival of 95 
patients receiving enteral nutrition was compared with 98 patients who continued oral 
feeding. There was no survival advantage with enteral feeding. However, the indication 
for enteral feeding and timing of PEG placement has not been described in the paper.  It 
also remains unclear whether gastrostomy was performed too late to demonstrate 
survival benefits. 
 
2.13 Discussion and Conclusion 
The impact of enteral feeding on QOL and survival of patients with MND is an issue of 
debate (Katzberg and Benatar, 2011; Miller et al., 2009). There are no randomised or 
quasi-randomised clinical trials assessing the outcomes of enteral feeding. In the 
65 
 
absence of randomised clinical trials, this chapter has attempted to report the outcomes 
of enteral feeding from observational studies, the majority of which are retrospective.   
The evidence for survival advantage with enteral feeding is weakly positive but 
inconclusive. Although some studies suggest survival advantage with enteral feeding 
(Chio et al., 1999; Chio et al., 2006; Czaplinski et al., 2006; Mazzini et al., 1995; 
Spataro et al., 2011), many others have failed to support these findings (Atassi et al., 
2011; Desport et al., 2000; Forbes et al., 2004; Mathus-Vliegen et al., 1994; Mitchell et 
al., 2006; Mitsumoto et al., 2003; Murphy et al., 2008; Sorenson et al., 2007; Strong et 
al., 1999; Zhang et al., 2012). All studies of enteral feeding in MND have been 
observational in nature.  Therefore, it is difficult to be certain whether the conflicting 
impact of enteral feeding on survival is due to different study designs, discrepancy in 
the rate of enteral feeding among various centres, bias or random error.  
Malnutrition is a common occurrence in MND and can significantly impact QOL, as 
patients are often exhausted, tired and spiritless (Greenwood, 2013; Korner et al., 2013). 
There are some studies which suggest stabilization of body weight and nutritional 
benefit with enteral feeding (Chio et al., 1999; Mazzini et al., 1995; Kasarskis et al., 
1999; Desport et al., 2000; Mitsumoto et al., 2003; Zhang et al., 2012). However, this 
evidence is weak (Katzberg and Benatar, 2011).  
The systematic review identified only four studies reporting changes in self-perceived 
QOL after enteral nutrition, of which only one was prospective (Mazzini et al., 1995) 
and the remaining retrospective in nature (Lou et al., 2010; Mitsumoto et al., 2003; 
Zamietra et al., 2012).  However, none of these studies were principally designed to 
investigate the association between enteral feeding and QOL.  There is a distinct lack of 
literature to support or refute enteral feeding for improving QOL in patients with MND. 
66 
 
It is interesting to note that despite the obvious burden of malnutrition in MND, most 
studies assessing the outcomes of enteral feeding were primarily not intended to 
determine the efficacy of enteral feeding as a therapeutic intervention. A careful 
dissection of the available literature has thus identified the need for a study to address 
the critical issue of impact of enteral feeding on quality of life of MND patients.  
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CHAPTER 3 
 
 
 
EPIDEMIOLOGY AND CLINICAL 
CHARACTERISTICS OF 
MOTOR NEURONE DISEASE IN 
LANCASHIRE AND SOUTH 
CUMBRIA 
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3.1 Introduction 
Motor Neurone Disease (MND) is a neurodegenerative disorder that predominantly 
affects middle-aged and elderly individuals with the mean age of onset varying from 55 
to 65 years (Wijesekera and Leigh, 2009). The median survival from symptom onset to 
death varies from 20 to 48 months (Beghi et al., 2011). For reasons that are not clear, 
there is a male preponderance with the male to female ratio of 1.5 (Beghi et al., 2006; 
McCombe and Henderson, 2010; Wijesekera and Leigh, 2009). The incidence ranges 
from 1.5 to 2.5 cases per 100,000 per year, although it varies between different studies 
and countries (Hoppitt et al., 2011; Logroscino et al., 2010; Mehal et al., 2013). 
The importance of descriptive epidemiology and detailed clinical characterisation of 
MND has emerged following the increasing recognition of clinical, pathological, 
prognostic and genetic heterogeneity of the illness (Logroscino et al., 2008; Ravits et 
al., 2013). It is also becoming obvious that such comprehensive clinical characterisation 
and epidemiological variations will form the basis of future genetic association studies 
designed to ascertain both risk and protective factors for MND (Logroscino et al., 2008; 
Renton et al., 2014). 
The range of studies on MND using population based registries can shed light on 
demographic characteristics, disease phenotype, geographical and temporal variations of 
the illness (Logroscino et al., 2008). There is lack of up to date population based data on 
MND in Lancashire and South Cumbria in North West England. It is also unclear 
whether the epidemiology and clinical characteristics of MND in this region are similar 
to our MND cohorts.  
The availability of the Preston MND database maintained by the Preston MND Care 
and Research Centre provided a unique opportunity to study the epidemiology, 
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demographic and clinical characteristics of MND in Lancashire and South Cumbria. 
This chapter presents the findings of a retrospective study that was undertaken to 
evaluate the demographic and clinical characteristics of MND in Lancashire and South 
Cumbria in North West England.  
 
3.2 Aim of the retrospective study 
The aim of this retrospective study was to evaluate the demographic and clinical 
characteristics of MND in Lancashire and South Cumbria in North West England. 
 
3.3 Objectives of the retrospective study 
The following were the objectives of the retrospective study: 
1. To determine the incidence of MND in Lancashire and South Cumbria. 
2. To review the demographic and clinical characteristics of MND in a large cohort 
of patients in Lancashire and South Cumbria. 
3. To evaluate the impact of enteral feeding on survival of patients with MND.  
 
3.4 Setting/Methods  
The study was conducted at the Preston MND care and research centre. The centre 
located at Royal Preston Hospital was inaugurated in 1993 and serves an approximate 
population of 1.6 million in Lancashire and South Cumbria (Mitchell et al., 2010). The 
fast-track diagnostic service was introduced in January 2005 in order to reduce 
diagnostic delays (Callagher et al., 2009; Mitchell et al., 2010). Patients are referred 
from seven different hospitals including Royal Preston Hospital, Furness General 
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Hospital, Royal Lancaster Infirmary, Burnley General Hospital, Blackburn Royal 
Infirmary, Blackpool Victoria Hospital, and Chorley District General Hospital.  
 
3.5 Ethics 
The study was approved by the National Research Ethics Service (NRES) Committee 
East Midlands - Nottingham 1 Research Ethics Committee, Nottingham (Appendix 3). 
As a host organisation, ethical approval was also obtained from Lancashire Teaching 
Hospitals NHS Foundation Trust (Appendix 4).  Ethical approval was also obtained 
from the Science, Technology, Engineering and Medicine (STEM) research degrees 
sub-committee, University of Central Lancashire (Appendix 5).  
 
3.6 Study area and study Population 
Patients diagnosed with MND by a Consultant Neurologist in Lancashire and South 
Cumbria district during the period January 2005 to December 2012 were recruited into 
the study. The study province had an approximate population of 1.6 million.  
 
3.7 Inclusion criteria  
Patients with a diagnosis of definite, probable, laboratory supported or possible MND as 
defined by the revised El Escorial criteria for diagnosis of Motor Neurone 
Disease/Amyotrophic Lateral Sclerosis (Brooks et al., 2000) were recruited. 
 
3.8 Exclusion criteria  
Patients, where the diagnosis of MND, were revised either due to atypical presentation 
or failure of symptom progression were excluded from the study.  
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3.8 Data Collection 
Patients were identified through the Preston MND database which is a computerised 
password protected resource.  Case notes of study subjects were scrutinized where 
available, for the following details: demographics, age of symptom onset, site of onset, 
date of diagnosis, date of feeding tube insertion (if applicable), situation at last follow 
up (dead or alive) and  date of death (if applicable). The date of diagnosis was taken as 
the date when the diagnosis of MND was disclosed to the patient. The extracted data 
were entered on a excel sheet. 
 
3.9 Statistical analysis  
All statistical analyses of association between clinical manifestation, survival and 
feeding tube insertion were analysed using Statistical Package for the Social Sciences 
(SPSS) version 22. Kaplan-Meier survival curves were used for survival analysis and a 
log-rank test was applied to compare the survival curves. A multivariate Cox regression 
model was used to assess the effectiveness of enteral nutrition in relation to survival. 
Patient characteristics were recorded as mean ± standard deviation and counts 
(percentages) and p values < 0.05 were considered statistically significant.  
 
3.10 Results 
The data source identified 407 patients.  67 cases with insufficient clinical information 
were excluded and the final cohort included 340 patients. 
 
3.10.1 Incidence  
The overall crude incidence rate was 3.15 per 100,000 population (95% CI 2.99-3.31).  
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3.10.2 Demographic characteristics 
Demographic profile 
Among the 340 patients, 181 (53.2%) were males and 159 (46.8%) females. A total of 6 
cases (1.8%) were under 40 years of age, 85 cases (25%) between 40 to 60 years of age, 
216 cases (63.5%) between 60 to 80 years of age and 33 cases (9.7%) over 80 years of 
age at symptom onset. These data suggest that MND is an age related disease. Table 3.1 
summarizes the age categories and distribution for sex and site of symptom onset.  
Table 3.1: Table showing the age, sex and site of symptom onset among 340 patients 
 
Age at symptom onset 
The overall mean age of onset was 67.28 years (S.D. 11.06; range 22.78-93.06). It was 
66.74 years (S.D. 11.50; range 22.78-89.46) for males and 67.89 years (S.D. 10.53; 
range 39.48-93.06) for females. The mean age of symptom onset was 69.22 years (S.D. 
11.13; range 45.97-93.06) for bulbar onset illness and 66.10 years (S.D. 10.88; range 
22.78-89.46) for limb onset illness.  
Age of onset 
(years) 
Bulbar 
 
Limb 
 
 Male 
 
Female 
 
Total 
(%) 
Male Female Total 
(%) 
< 40 1 0 1   (0.3) 4 1 5 (1.5) 
40 - 60 12 14 26 (7.6) 32 27 59 (17.4) 
60 - 80 34 47 81 (23.8) 86 49 135 (39.7) 
>80 7 14 21 (6.2) 5 7 12 (3.5) 
Total 54 75 129 (37.9) 127 84 211 (62.1) 
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Symptom onset was rare before the age of 40 years occurring in only 6 patients, of 
which 5 were males. There was a dramatic increase after 60 years of age. The onset 
increased with increasing age in both sex groups and declined rapidly after the age of 80 
years. Figure 3.1 illustrates the illness onset in various age groups.  
 
Figure 3.1: Pie chart depicting age groups at symptom onset 
 
Age at diagnosis and diagnostic delay 
The mean age at diagnosis was 68.51 years (S.D 10.93; range 23.85-93.58); 68.07 years 
(S.D. 11.35; range 23.85-89.84) for males and 68.85 years (S.D 10.41; range 40.99-
93.58) for females. Median delay between symptom onset and diagnosis was 0.86 years 
(range 0.50-1.24). 
 
Duration of illness 
Median overall illness duration was 1.98 years (range 1.18-3.05); 2.06 years (range 
1.20-3.10) for males and 1.97 years (range 1.15-2.99) for females. 
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3.10.3 Clinical characteristics  
Limb onset motor neurone disease  
A total of 211 (62.1%) cases had limb onset of the illness and presenting features 
included limb clumsiness and muscle weakness of gradual onset, starting either 
proximally or distally. Limb onset MND was more common in males. 127 cases were 
males and 84 cases were females. The vast majority of limb onset cases (135 cases; 
63.9%) were in the 60 - 80 year age group.   
The presenting symptoms in the upper limb included impaired hand dexterity, poor grip, 
cramps, muscle weakness and wasting. Symptoms in the lower limbs included difficulty 
in walking, heaviness in the legs, cramps, tendency to trip, foot drop, muscle weakness 
and wasting. Figure 3.2 illustrates the  distribution by age of symptom onset and gender 
in limb onset MND. The data show that significantly (p<0.05) more patients within the 
age group 60 – 80 years had limb onset of the illness as compared to other age groups. 
 
Figure 3.2: Bar charts showing gender and age distribution of limb onset MND 
(n=211), *p <0.05 for males as compared to females.  
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Bulbar onset motor neurone disease 
A total of 129 (37.9%) cases had bulbar onset of the illness and presenting features 
included dysarthria and/or difficulty swallowing. Bulbar onset illness was more 
common in females. A total of 75 cases were females and 54 cases were males.  
The number of patients with bulbar onset illness increased significantly (p<0.05) with 
increasing age and 102 (79.1%) of cases were more than 60 years of age. Onset of 
bulbar onset illness was very rare before the age of 40 years and declined after the age 
of 80 years.  Figure 3.3  illustrates the  distribution by age of symptom onset and gender 
in bulbar onset MND. The data further reveal that significantly (p<0.05) more cases 
within the age group 60 – 80 years had bulbar onset of the illness compared to other age 
groups.  
 
 
Figure 3.3:  Bar charts showing gender and age distribution of bulbar onset MND 
(n=129), *p <0.05 for females as compared to males.  
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3.10.4 Overall Survival characteristics 
The median survival from symptom onset was 721 days (95% CI 637.98-804.02) for 
limb onset and 731 days (95% CI 611.99-850.00) for bulbar onset illness. Log-Rank 
analysis revealed no significant difference in survival between bulbar and limb onset 
MND (Log-Rank χ2 (1) = 0.15, p=0.70).  
The overall one year survival rate was 82.2% (SE 0.034) for limb and 82.5% (SE 0.026) 
for bulbar onset MND.  The overall five year survival rate was 5.2% (SE 0.02) for limb 
and 7.8% (SE 0.02) for bulbar onset illness. 
 
3.10.5 Enteral Feeding and survival  
A total of 91 (26.8%) patients received enteral feeding, of which 61 (67.0%) had bulbar 
onset of the illness. The remaining had limb onset MND. The main indication for 
enteral feeding was dysphagia and/or progressive weight loss.    
Cox regression analysis was used to assess the effect of various covariates on survival 
following enteral feeding. Enteral nutrition was not associated with a statistically 
significant survival advantage, (Log-Rank χ2 (1) = 1.73, p=0.19) after adjusting for 
effects of gender, onset age, onset site, time from onset to diagnosis and riluzole 
treatment (Figure 3.4).  
The regression coefficients, degrees of freedom, p-values and odds ratios for each 
covariables are included in Appendix 6. Three of the covariates reliably predicted 
survival time at p<0.001: onset age, delay from symptom onset to diagnosis and 
riluzole. Younger patients treated with riluzole at an early stage were more likely to 
survive longer. Survival at one year with enteral nutrition was 82% (SE 0.04) and 
without enteral nutrition 83% (SE 0.02).  
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Figure 3.4: Kaplan-Meier cumulative survival curve from symptom onset in patients 
with enteral feeding (EF) versus no EF (n= 340; EF = 91; No EF = 249). 
 
A further Log-Rank analysis revealed no significant difference in survival time between 
bulbar onset and limb onset (Log-Rank χ2 (1) = 0.57, p = 0.45), irrespective of whether 
patients received enteral nutrition or not (Log-Rank χ2 (1) = 0.05, p = 0.82). Median 
(95% CI limits) survival times for limb onset illness with and without enteral nutrition 
were 777 (498.67-1055.13) days and 718 (625.02-810.98) days, respectively. Median 
survival times for bulbar onset with and without enteral nutrition were 799 (677.64-
920.36) days and 645 (427.82-862.19) days respectively.  
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3.11 Discussion 
The clinical features of the study cohort are largely similar to those described in 
previous population based studies (Bandettini di Poggio et al., 2013; Fang et al., 2009; 
Imam et al., 2010; Logroscino et al., 2010; Mehal et al., 2013; Murphy et al., 2008; 
O'Toole et al., 2008; Pradas et al., 2013; Traynor et al., 2000; Zoccolella et al., 2006). 
There was a slight male preponderance. The data show that bulbar onset was identified 
in about one third of patients, being more common among females.  Median overall 
illness duration was 1.98 years (range 1.18-3.05 years). 
The mean age of symptom onset was 67.28 years (S.D. 11.06; range 22.78-93.06). 
Onset was rare before the age of 40 years with a significant (p<0.05) and dramatic 
increase after 60 years of age. The onset increased with increasing age and declined 
rapidly after the age of 80 years, a finding that has been reported in other studies 
(Alonso et al., 2009; Logroscino et al., 2008; Pradas et al., 2013). This may be due to 
the fact that the patients die by the age of 80 years. In addition, the decline in trend in 
elderly has been attributed to a number of factors including difficulty in case 
ascertainment due to competing comorbidities, difficult access to specialised care and 
loss of follow up or to a more aggressive illness ending in death before the diagnosis of 
MND is secured (Beghi et al., 2006).  
The incidence rate of 3.15/100,000 is similar to other population based studies 
(Bandettini di Poggio et al., 2013; Imam et al., 2010; Logroscino et al., 2008; 
Logroscino et al., 2010; Murphy et al., 2008; Pradas et al., 2013; Traynor et al., 1999). 
The incidence in the study area in early nineties was 1.76/100 000 population (Mitchell 
et al., 1998).  Some studies have also shown an increase in incidence rate over the past 
several decades and this may be due to improvements in case ascertainment and better 
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diagnostic methods (Fang et al., 2009; Murphy et al., 2008; Seljeseth et al., 2000).  
MND care in the study region is centralized in one hospital and the majority of cases 
were prospectively recorded which may have improved case ascertainment.  
The median diagnostic delay from symptom onset was 0.86 years (range 0.50-1.24 
years). The diagnostic delay is similar to other studies which report a median diagnostic 
delay ranging from 0.75 to 1.2 years (Cellura et al., 2012; Chio, 1999; Kraemer et al., 
2010; Mitchell et al., 2010). Delays in diagnosis has significant implications in 
accessing appropriate care, formulating individualized supportive management plan and 
difficulty in planning future care (Chio, 1999). 
Bulbar onset illness was more common in elderly females, a finding that has been 
described in other studies (Chio et al., 2009b; Traynor et al., 1999). Bulbar onset illness 
is usually associated with a worse prognosis (Chio et al., 2002; Norris et al., 1993; 
Traynor et al., 2000). However, this study did not find a significant survival difference 
between bulbar onset and limb onset illness, irrespective of whether or not they received 
enteral feeding. The retrospective nature of this study does not provide any clues to 
explain this finding and needs to be evaluated in a prospective study.  However, bulbar 
onset patients were more likely to require enteral feeding than limb onset cases, a 
finding reported in many other studies (Atassi et al., 2011; Forbes et al. 2004; 
Georgoulopoulou et al., 2013).  
Enteral feeding was not associated with a survival advantage, a finding that is in 
keeping with the results of many other studies (Atassi et al., 2011; Desport et al., 2000; 
Forbes et al., 2004; Mathus-Vliegen et al., 1994; Mitchell et al., 2006; Mitsumoto et al., 
2003; Murphy et al., 2008; Sorenson et al., 2007; Strong et al., 1999; Zhang et al., 
2012). However, the present results also are in disagreement with the findings of few 
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other studies that report a survival advantage with enteral feeding (Chio et al., 1999; 
Chio et al., 2006; Czaplinski et al., 2006; Mazzini et al., 1995; Spataro et al., 2011).  
Previous studies that have demonstrated survival advantage with enteral feeding have 
their own limitations.  Mazzini et al. (1995) reported survival of 38 months versus 30 
months (p<0.03) in a prospective study comparing 31 patients undergoing gastrostomy 
with 35 control patients. The control group had refused the procedure. However, 
multivariable regression analysis to assess possible confounders was not undertaken in 
this study.  
Chio et al. (1999) demonstrated a survival advantage with enteral feeding in a case 
control study of 50 patients undergoing gastrostomy who were matched with 100 
historical controls. Survival advantage was noted only in bulbar onset but not spinal 
onset illness.  
In a retrospective cohort study of 1041 patients of which 275 received gastrostomy, 
Czaplinski et al. (2006) demonstrated significantly improved survival rate with enteral 
feeding. However, the median survival was analysed from symptom onset rather than 
from the point of gastrostomy. The lack of survival statistics from the point of 
gastrostomy makes it difficult to ascertain the true impact of enteral feeding on survival.  
Chio et al. (2006) prospectively followed 221 patients with MND over a two year 
period. Patients not receiving gastrostomy had a hazard ratio of 3.38 (p=0.0006) for 
death compared to 52 patients with gastrostomy. However, it is unclear whether the 
clinical characteristics of the gastrostomy cohort were similar or different to the group 
not receiving gastrostomy.  
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In a prospective study by Spataro et al. (2011), it was uncertain whether the reported 
survival advantage in 76 patients who underwent gastrostomy was due to either enteral 
feeding or early active management as earlier diagnosis and timely access to 
multidisciplinary care is an independent prognostic factor for survival (Chio et al., 
2006; Traynor et al., 2003).  
For methodological and ethical reasons, it is difficult to demonstrate a survival 
advantage with enteral feeding. A true comparison can only be made with cases that 
require enteral feeding, but do not receive it. However, for obvious ethical reasons, a 
randomized controlled study cannot be undertaken as it would be immoral to deny 
enteral feeding to those who need it.   Comparison can therefore only be made with 
patients who refuse the procedure but such patients are uncommon.  
 
3.12 Conclusion 
The present results show that the overall crude incidence of MND was 3.15 per 100,000 
population. The mean age of onset was 67.28 years (S.D. 11.06; range 22.78-93.06). 
The number of new cases increased with increasing age and declined rapidly after the 
age of 80 years. There was a slight male preponderance. The presentation was limb 
onset in 62.1% and bulbar onset in 37.9% cases. Bulbar onset was more frequent among 
females.  Median survival was 1.98 years (range 1.18-3.05 years). 
A total of 91 (26.8%) patients received enteral feeding of which 67% were bulbar onset. 
Enteral feeding was not associated with a statistically significant survival advantage (χ2 
(1) = 1.73, p = 0.19). Median (95% CI limits) survival times for limb onset illness with 
and without enteral feeding were 777 (498.67-1055.13) days and 718 (625.02-810.98) 
days respectively. Median survival times for bulbar onset with and without enteral 
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feeding were 799 (677.64-920.36) days and 645 (427.82-862.19) days respectively. In 
conclusion, the present results show that enteral feeding is not associated with survival 
advantage.  
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CHAPTER 4 
 
 
 
 
ENTERAL NUTRITION: 
IMPACT ON  
QUALITY OF LIFE 
 
 
 
84 
 
4.1 Introduction 
‘Quality of life’ is a ubiquitous and multifaceted concept with a wide range of 
definitions and interpretations (Brotherton and Judd, 2007; Rapley, 2003). It is an 
ambiguous and ill-defined term due to its holistic and subjective dimension and means 
differently to different individuals, depending on the context and subject of application 
(Fayers and Machin, 2007).  
Motor Neurone Disease (MND) is a fatal neurodegenerative illness and management is 
mainly supportive, focussed on preserving independence and maintaining and/or 
enhancing QOL of patients (Andersen et al., 2012). The significance of QOL as a major 
outcome variable has therefore become increasingly evident in the management of 
MND (Clarke et al., 2001). The perspectives and wishes of patients are of paramount 
importance and treatment efforts should be directed towards improving quality rather 
than just quantity of life (Bozzetti, 2008). Measuring and monitoring QOL is therefore 
essential in appraising the efficacy of any supportive treatment (Brooks, 1997; Neudert 
et al., 2004). 
Placement of a gastrostomy feeding tube has important ethical concerns and the 
decision to offer gastrostomy should depend on whether a patient will derive any actual 
benefit from it (Good et al., 2014). Enteral feeding through a gastrostomy tube is 
associated with number of complications and psychosocial inconveniences (Blomberg 
et al., 2012; Potack and Chokhavatia, 2008; Rogers et al., 2007). Assessing QOL is 
therefore important to optimize the adequacy of enteral feeding to the needs and 
expectations of every individual patient. 
Enteral feeding is routinely offered to patients with MND but the there is no evidence to 
support or refute enteral feeding for maintaining or improving QOL.  This chapter will 
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present the findings of a prospective study that was undertaken over a three year period 
from February 2012 to September 2014 to explore the experiences of MND patients 
with enteral feeding and its impact on their quality of life. 
 
4.2 Aim of the prospective study 
The aim of the study was to investigate the impact of enteral feeding delivered via 
gastrostomy tube on QOL of patients with MND in Lancashire and South Cumbria in 
North West England. 
 
4.3 Objectives of the prospective study 
The objectives of the prospective study are: 
1. To explore patients’ experiences with enteral nutrition. 
2. To explore the impact of enteral nutrition on quality of life. 
3. To examine change in nutritional status through measurement of body mass 
index at the time of diagnosis, pre and post enteral feeding. 
 
4.4 Setting/Methods 
The study was conducted at the Preston MND Care and Research Centre. The Centre 
located at Royal Preston Hospital, United Kingdom, serves an approximate population 
of 1.6 million in Lancashire and South Cumbria in North West England.  
Patients were reviewed by the MND team on a three monthly basis and assessed for 
nutritional and respiratory impairment. The facility also operated a unique service 
delivery model which provided outreach nurse-led clinics in hospice settings and home 
visits, if patients were unable to travel because of their disability. During the follow up 
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visits, weight and forced vital capacity were recorded. However, it was not possible to 
record weight in all cases, particularly if patients were bedbound and/or there was no 
access to a hoist weighing scale.  Functional and QOL assessment were also undertaken 
during the follow up visits by completing the ALSFRS-R and ALSAQ-40 
questionnaires. 
 
4.5 Ethics 
The study was approved by the National Research Ethics Service (NRES) committee 
East Midlands - Nottingham 1 Research Ethics Committee (Appendix 3). As a host 
organisation for the study, ethical approval was also obtained from the research 
directorate and clinical studies centre of the Lancashire Teaching Hospitals NHS 
Foundation Trust (Appendix 4).  
Ethical approval was also obtained from the Ethics Committee for Science, Technology, 
Engineering and Medicine (STEM) ethics committee, University of Central Lancashire 
(Appendix 5).  
Lancashire Teaching Hospitals NHS Foundation Trust provided public liability 
insurance cover for the work.  
 
4.6 Study subjects 
Patients with MND referred for gastrostomy were considered for the study. Patients 
were identified through the Preston MND and Research Centre by the researcher or a 
member of the MND team. 
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4.6.1 Purposive sampling 
All participants were selected through a non-probability purposive sampling technique 
where patients with MND referred for gastrostomy were assessed for eligibility. 
Purposive sampling is a non-probability sampling method which involves the deliberate 
selection of certain subjects who represent the desired population to be included in the 
study (Teddlie and Yu, 2007). A purposive sample is constructed to serve a very 
specific need or purpose and targets a specific group of individuals, particularly when 
the desired population for recruitment in the study of interest is rare (Teddlie and Yu, 
2007). 
MND is an uncommon condition and only a proportion of patients with the condition 
receive enteral nutrition. A purposive sampling method was therefore employed to 
address the specific question of whether enteral feeding improves quality of life in this 
rare study population.  
 
4.7 Inclusion Criteria 
Patients diagnosed with definite, probable, laboratory supported or possible MND as 
defined by the revised El-Escorial diagnostic criteria (Brooks et al., 2000) and referred 
for gastrostomy. 
 
4.8 Exclusion Criteria 
The exclusion criteria for the study were as follows: 
a. Patient declined gastrostomy. 
b. Contraindications to gastrostomy. 
88 
 
4.9 Recruitment and study design 
Patients with MND referred for gastrostomy were informed about the study by the 
researcher or a staff member of the MND team. Interested patients were assessed for 
eligibility by the researcher based on the inclusion and exclusion criteria as outlined 
above.  
Eligible patients were given a letter of invitation (Appendix 7) and a comprehensive 
patient information sheet (Appendix 8) explaining the details of the study and 
requesting them to contact the researcher, if they were interested in participating in the 
study. In order to ensure that the perspectives of participants were accurately 
represented, the patient information sheet and letter of introduction clearly outlined the 
intent and purpose of the study.  
Interested patients were also given the opportunity to speak to the researcher if they had 
any questions. The study also had the option of sending one reminder to those patients 
who did not contact the researcher within four weeks of the original invitation 
(Appendix 9). Patients were also informed about the voluntary nature of their 
participation and that they may decline to participate in the study without the risk of 
compromising clinical care.  They were also made aware of their right to withdraw from 
the study at any time, including during follow up, without having to provide any 
explanations.  
A signed consent was obtained from the participants to confirm their willingness to 
participate in the study (Appendix 10). Participants who were unable to communicate 
due to dysarthria or loss of ability to speak coherently were given the opportunity to 
communicate by writing or with the aid of an iPad or other assistive communication 
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devices. Participants who were unable to sign the consent form due to hand weakness 
permitted their next of kin to sign the form in their presence.  
Patients who consented to participate in the study had their age, gender, height, weight 
and forced vital capacity recorded, where possible. Functional and QOL assessment was 
undertaken using the ALSFRS-R (Appendix 11) and the ALSAQ-40 (Appendix 12). 
With the patient’s consent, a letter was sent to their general practitioner informing them 
about the patient’s participation in the study (Appendix 13). 
The study participants were followed up at 3, 6 and 12 months following the procedure. 
The letter of invitation (Appendix 7) was posted along with the Liverpool PEG 
questionnaire (Appendix 14) four weeks before the scheduled follow up appointments.  
The letter was intended to serve as a reminder to the patient that they were invited to 
complete the PEG questionnaire in order to understand their experiences with enteral 
feeding and its impact on their QOL at different timeframes. Participants were requested 
to bring the completed questionnaire to the follow up visits.  
Participants who were not able to bring the completed PEG questionnaire to the follow 
up appointments were given the opportunity to complete it during the appointment.  If 
patients were unable to travel to the clinics because of their disability, the assessments 
were undertaken during the scheduled home visits by a member of the MND team.  
Participants who were unable to complete the PEG questionnaire due to limb weakness 
permitted their next of kin or a staff member of the MND team to transcribe their 
responses. In addition to the PEG Questionnaire, the ALSFRS-R and ALSAQ-40 forms 
were also completed during the scheduled follow up visits.  The weight was also 
recorded, where possible, during the follow up visits. The recruitment strategy and 
study flow chart is outlined in figure 4.1.  
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Figure 4.1: Flow chart showing patient recruitment  
Informed Consent obtained   
No response Reminder Letter 
No further action Not willing to participate 
Patient interested to participate  
Baseline: at time of gastrostomy  
Weight and height 
ALSFRS-R 
ALSAQ-40 
 
 
ALSAQ
 Baseline – at time of gastrostomy  
Weight  
ALSFRS-R  
  
No response at 4 weeks  
3, 6 and 12 months follow up 
Weight  
ALSFRS-R 
ALSAQ-40 
Liverpool PEG Questionnaire 
 
Liverpool PEG Questionnaire 
One open question (please see protocol) 
 
  
End of study 
Preston MND Care and Research Centre: 
Patient identification and information 
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4.10 Instruments used in the study 
Measuring change in a patient’s health status is central to the management of any 
condition as well as designing research studies (Munsat, 1996). The measurement tools 
should be reliable, valid, sensitive to change, convenient, safe, cost and time efficient 
(Brooks, 1997; Munsat, 1996). The following section provides an overview of the 
instruments used in this study.   
 
4.10.1 Amyotrophic Lateral Sclerosis Functional Rating Scale – Revised   
(ALSFRS -R) 
The ALSFRS-R, a validated, questionnaire-based, 12 item scale was used for evaluating 
the functional status and functional change in patients with MND (Cedarbaum et al., 
1999). Each item in the ALSFRS-R was scored from 0 (worst function) to 4 (normal 
function). The scores were added to generate a total score ranging from 0, indicating 
worst function, to 48, which implied normal function. The bulbar subscale consisted of 
the domains of swallowing, speech and salivation. Handwriting, cutting food, dressing 
and hygiene were included under the fine motor domain. Questions relating to turning 
in bed, walking and climbing stairs measured gross motor function. Dyspnoea, 
orthopnoea and the need for ventilatory support were integrated under the respiratory 
domain (Cedarbaum et al., 1999).      
 
4.10.2 Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ - 40)  
The ALSAQ-40, a validated, disease specific measure of QOL was used in this study to 
measure the subjective well-being of patients with MND. The scale had also been 
validated for use in other languages (Maessen et al., 2007).  It was the only self-reported 
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QOL instrument designed specifically for use in MND.  The questionnaire had 40 items 
incorporated in five distinct areas of health: physical mobility (10 items), activities of 
daily living (10 items), eating and drinking (3 items), communication (7 items) and 
emotional functioning (10 items). Patients were asked to respond on a five point Likert 
type scale how true each item statement had been in the past two weeks (Jenkinson et 
al., 1999; Jenkinson et al., 2007). The answers from each of the five scales were then 
collated into a summary scale. 
The scale had been demonstrated to show high internal reliability and construct and 
content validity (Jenkinson et al., 1999; Jenkinson et al., 2000; Jenkinson et al., 2007). 
ALSAQ-40 scores were also sensitive to changes that have an impact on the overall 
health status of patients over time (Jenkinson et al., 1999; Jenkinson et al., 2003; 
Norquist et al., 2004). However, ALSAQ-40 did not incorporate areas of 
religious/spiritual beliefs which are important to many patients with MND (Bremer et 
al., 2004; Walsh et al., 2003). Nonetheless, ALSAQ-40 was more widely used than 
many other QOL measurement tools in MND (Jenkinson et al., 2007; Palmieri et al., 
2010). The ALSAQ-40 was the instrument of choice for assessment of QOL at the 
Preston MND Care and Research Centre.  
 
4.10.3 Liverpool Percutaneous Endoscopic Gastrostomy (PEG) Questionnaire 
The Liverpool PEG Questionnaire had been designed to look at experiences of patients 
with PEG feeding (Rogers et al., 2007). The questionnaire involved multiple close 
ended questions aimed at identifying the problems of gastrostomy feeding and its 
impact on QOL. Patients were asked to respond on a four point Likert type scale for 
majority of the questions.  
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The questionnaire also had an open question to capture any other problems or concerns 
with PEG.  The questionnaire was originally designed for use in patients with PEG in 
head and neck cancers and needs further validation (Rogers et al., 2007). There were no 
other relevant gastrostomy specific questionnaires to explore patients’ experiences with 
gastrostomy feeding.  
The commonly used QOL instruments did not provide specific information regarding 
the impact of nutritional problems and intervention on an individual’s QOL. This study 
had therefore incorporated  an open question  that reads “How would you describe your 
quality of life since the insertion of your feeding tube?” aimed at capturing  in-depth 
data about patients’ perspectives about tube feeding and its implications on their QOL. 
It was hoped that this single open question would encourage the expression of 
subjective perception and self-appreciation of QOL following enteral feeding.  This 
open question was added to the end of the Liverpool PEG questionnaire. 
 
4.11 Data Collection 
Case notes of participants were scrutinized, for the following details: demographics, age 
of symptom onset, site of onset, weight at diagnosis and date of diagnosis. The results 
of ALSFRS-R, ALSAQ-40 and PEG questionnaires were entered on a excel sheet. 
When possible, weight was recorded. However, some participants could not be weighed 
as they were either bedbound and/or there was no access to a hoist weighing scale. 
 
4.12 Statistical analysis  
Data were managed with the aid of SPSS version 22.  Patient characteristics were 
recorded as mean ± standard deviation and counts (percentages). The total score was 
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computed for ALSFRS-R. Scores were computed for the ALSAQ-40 scale and its 
emotional functioning domain. The mean scores at diagnosis, gastrostomy and 12 
months were compared using the unpaired student’s t test.   Data from the PEG 
questionnaire were computed to determine the percentage of participants encountering 
the itemized inconveniences. The qualitative data relating to patients’ perceptions about 
the impact of enteral feeding on their QOL were subjected to thematic analysis.  
 
4.13 Results 
A total of 23 patients were approached to take part in the study. However, 2 patients 
declined to participate and 21 patients were recruited. One participant withdrew before 
the 3 month assessment and a second participant withdrew after completion of 6 month 
assessment. One patient was lost to follow up after completion of 6 month assessment. 
A total of 8 participants died during the study period. Another 17 patients completed 6 
months of the study and 10 patients completed the entire 12 months of study.   
 
4.13.1 Participant characteristics 
Among the 21 participants, 8 (38.1%) were males and 13 (61.9%) were females. The 
overall mean age of symptom onset was 64.23 years (S.D. 12.27; range 39.60-79.00). It 
was 62.69 years (S.D. 14.09; range 39.60-76.44) for males and 65.18 years (S.D. 11.51; 
range 43.84-79.00.) for females. The mean age of symptom onset was 66.95 years (S.D. 
8.56; range 48.00-77.52) for bulbar onset illness and 60.61 years (S.D. 15.58; range 
39.60-79.00) for limb onset illness. 
The illness was of limb onset in 9 (42.9%) cases and bulbar onset in 12 (57.1%) cases.  
Among the limb onset cases, 5 (55.6%) were males and 4 (44.4%) were females. 
95 
 
Among the bulbar onset cases, 3 (25%) were males and 9 (75%) were females. Median 
duration between symptom onset and gastrostomy was 490 days (95% CI 252.33- 
1303.68 days).  
The indications for gastrostomy were: dysphagia for 4 patients, weight loss for 1 patient 
and combined dysphagia and weight loss for the remaining 16 patients. 4 patients had 
received RIG and 17 had received PEG.  All patients with RIG had significantly 
impaired respiratory function as indicated by low FVC, the highest recorded in this 
group being 41% of the predicted value.  
  
4.13.2 Survival characteristics 
There were no deaths within 30 days of gastrostomy, 2 deaths within 90 days, 1 further 
death within 180 days and 5 additional deaths within 365 days of gastrostomy. Among 
the 8 participants who died during the study period, median illness duration was 652 
days (95% CI 385.71-1557.04).  Median survival from gastrostomy to death was 210 
days (95% CI 109.14 - 277.61).  
 
4.13.3 Nutritional characteristics 
The mean BMI at diagnosis was 25.2 kg/m
2
 (S.D. 3.10; range 23.8-26.7 kg/m
2
). It was 
22.4 kg/m
2
 (S.D. 3.25; range 20.9-23.9 kg/m
2
) at gastrostomy, indicating a significant 
weight loss from diagnosis (p=0.007). The BMI stabilised following gastrostomy and 
the decline in BMI at 12 months following gastrostomy was not statistically significant 
(p=0.310) (Figure 4.2).  
The mean BMI at 3, 6 and 12 months post gastrostomy were 21.5 kg/m
2
 (S.D. 3.01; 
range 19.9-23.2 kg/m
2
), 21.1 kg/m
2
 (S.D. 2.52; range 19.7-22.6 kg/m
2
) and 20.89 kg/m
2
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(S.D. 2.99; range 17.5-24.2 kg/m
2
) respectively. These data clearly demonstrates that 
the disease is leading to malnutrition over time. 
 
Figure 4.2: Bar charts showing the mean BMI (+_  SE)  at diagnosis (n=20), gastrostomy 
(n=21) and 3 (n=15), 6 (n=14) and 12 (n=6)  months following gastrostomy. Note the 
BMI stabilised following gastrostomy. *p<0.007 at PEG compared to p=0.310 at 12 
months following PEG. 
 
4.13.4 ALSFRS -R scores 
The mean ALSFRS-R scores declined over time (Figure 4.3). The mean score at 
diagnosis was 39.39 (SD 6.34; range 36.23-42.54); 31.05 (SD 6.99; range 27.87-34.23) 
at gastrostomy and 18 (SD 5.25; range 14.25-21.75) at 12 months post gastrostomy.  
The decline in mean score from diagnosis to gastrostomy was statistically significant 
(p<0.001). There was also a significant difference in the scores between gastrostomy 
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and 12 months post gastrostomy (p=0.043), indicating a substantial decline in functional 
and clinical status over time.  
 
. 
 
Figure 4.3:  Bar charts showing the mean ALSFRS-R scores (+_  SE)  at diagnosis 
(n=18), gastrostomy (n=21) and 3 (n=18), 6 (n=17) and 12 (n=10) months following 
gastrostomy. Note the gradual and signficant decline in scores with time. *p<0.001 at 
PEG compared to p<0.05 at 12 months following PEG. 
 
4.13.5 ALSAQ - 40 scores 
The ALSAQ-40 scores increased with illness progression indicating deterioration of 
subjective well-being (Figure 4.4).  The mean ALSAQ-40 score at diagnosis was 61.94 
(SD 24.78; range 48.81-75.07) and 79.70 (SD 29.08; range 66.09-93.31) at gastrostomy. 
The difference in these mean scores was significant (p<0.05). The mean score at 12 
months post gastrostomy was 102.90 (SD 20.17; range 88.49-117.11) and the difference 
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was significant when compared to the mean score at gastrostomy (p=0.03), indicating a 
progressive decline in subjective functioning and well-being of patients.  
 
 
Figure 4.4: Bar charts showing the mean ALSAQ-40 scores (+_  SE)  at diagnosis (n=16), 
gastrostomy (n=20) and 3 (n=18), 6 (n=17) and 12 (n=10) months following 
gastrostomy.  Note the gradual and significant increase  in scores with time. *p<0.05 for 
PEG as compared to p=0.03 at 12 months post PEG. 
 
 
 
The mean emotional functioning sub-score of ALSAQ-40 at diagnosis was 13.00 (SD 
7.62; range 8.94-17.06). The sub-scores at gastrostomy insertion and 3, 6 and 12 months 
post gastrostomy were 15.45 (SD 9.60; range 10.96-19.94), 11.67 (SD 9.46; range 6.96-
16.37), 11.35 (SD 6.86; range 7.82-14.88) and 10.70 (SD 7.36; range 5.44-15.96), 
respectively.   
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Despite a significant increase in the overall mean ALSAQ-40 scores following 
gastrostomy (p<0.05), the mean emotional functioning sub-scores remained fairly stable 
during the study period (Figure 4.5).  The difference in mean scores between 
gastrostomy and 12 months was not significant (p=0.181). This indicates that enteral 
feeding ameliorates the decline in emotional functioning. 
 
 
Figure 4.5: Bar charts showing the mean emotional functioning subscores (+_ SE) at 
diagnosis (n=16), gastrostomy (n=20) and 3 (n=18), 6 (n=17) and 12 (n=10) months 
post gastrostomy.  Note there is no signficant decline in emotional functioning 
subscores from gastrostomy . *p=0.181 for difference in scores from PEG to 12 months 
post PEG.  
 
 
4.13.6 Liverpool PEG Questionnaire results 
Gastrostomy feeding tube was used regularly by 10 (55.6%) participants at 3 months, 11 
(64.7%) at 6 months and 6 (60%) at 12 months. The tube was not used ‘at all’ by 3 
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participants each at 3 and 6 months. At 12 months follow up, 1 participant was still not 
using the feeding tube. The rest of the patients were using the tube very occasionally (2 
participant each at 3 and 12 months) or frequently (3 each at 3 and 6 months; 1 at 12 
months).    
The majority reported ‘little’ or no problem ‘at all’ with the tube. The problems were 
generally more common in the first 3 months following gastrostomy. Only a small 
minority felt that the problems were significant (‘very much’).  Clinical complications 
including leakage, pain, redness/irritation, bleeding and infection were common, 
occurring in up to 70% of the study participants. However, majority of the participants 
perceived this to be a ‘little’ problem.   Table 4.1 details the problems encountered by 
participants.  
More than 70% reported no interference with their family life, intimate relationships, 
social activities and hobbies. Up to 40% of the participants had difficulty in keeping the 
gastrostomy site clean. Approximately 30% reported altered appearance and up to a 
quarter felt that the tube had an impact on the type of clothes they wore. More than 70% 
of participants had no difficulties ‘at all’ in using the gastrostomy tube. At 12 months, 
only 10% perceived the gastrostomy tube to be a ‘little’ difficulty. 
A total of 4 participants required one change of gastrostomy tube and 1 participant 
required 4 changes due to problems with the tube. Despite the problems associated with 
gastrostomy, a vast majority did not wish for the gastrostomy tube to be removed. Only 
11.1% (n=2) and 17.7% (n=3) wished for the tube to be removed at 3 and 6 months 
respectively. No one wished for the tube to be removed at 12 months. It is of note that 
none wished ‘very much’ for the tube to be removed at any point. 
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Table 4.1: Table showing the Liverpool (PEG) Questionnaire: Problems encountered 
by participants at 3, 6 and 12 months post gastrostomy (% of responders)  
 How much of a problem was the PEG to you (% of responders) 
3 months (n= 18) 6 months (n=17) 12 months (n=10) 
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Pain /  
Discomfort 
50 38.8 5.6 5.6 52.9 41.2 5.9 0 60 30 10 0 
Leakage 
 
38.9 44.4 11.1 5.6 41.2 52.9 0 5.9 40 50 10 0 
Dirtying of your 
clothes by leakage  
72.2 22.2 0 5.6 64.7 29.4 5.9 0 70 30 0 0 
Redness / 
 irritation 
 
50.0 38.9 0 11.1 35.3 47.1 17.6 0 30 50 20 0 
 
Blockage 
 
 
 
 
100 0 0 0 94.1 5.9 0 0 90 0 10 0 
Bleeding 
 
61.1 33.3 5.6 0 58.8 35.3 5.9 0 50 50 0 0 
Infection 
 
77.8 16.6 0 5.6 76.5 23.5 0 0 100 0 0 0 
Tube splitting 
 
94.4 0 0 5.6 94.1 5.9 0 0 100 0 0 0 
Falling out 
 
100 0 0 0 88.2 11.8 0 0 90 0 0 10 
Keeping the PEG and 
PEG site clean 
72.2 11.1 5.6 11.1 76.5 0 11.8 11.8 60 20 0 20 
Appearance 83.3 11.1 0 5.6 76.5 17.6 0 5.9 70 20 10 0 
Types of clothes worn 77.8 22.2 0 0 52.9 23.5 17.6 5.9 80 10 0 10 
Difficulties using the 
PEG tube 
77.8 5.6 5.6 11.1 70.6 17.6 5.9 5.9 90 10 0 0 
Interference with 
family life 
77.8 22.2 0 0 76.5 17.6 5.9 0 80 20 0 0 
Interference with 
intimate relationships 
94.4 5.6 0 0 94.1 0 5.9 0 100 0 0 0 
Interference with 
social activities 
72.2 27.8 0 11.1 76.5 11.8 5.9 5.9 90 0 10 0 
Interference with 
hobbies or leisure time 
88.9 11.1 0 0 88.2 0 11.8 0 90 10 0 0 
How much has the 
PEG affected QOL 
50.0 27.8 0 22.2 58.8 17.6 11.8 11.8 50 20 0 30 
How much do you 
think about your PEG 
44.4 33.3 16.7 5.6 52.9 23.5 23.5 0 50 50 0 0 
Do you wish the PEG 
could be removed            
88.9 11.1 0 0 82.3 11.8 5.9 0 100 0 0 0 
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This study also identified a major shortcoming of the Liverpool PEG questionnaire. The 
question “How much has the PEG affected QOL” is crucial to capture patients’ 
perception of enteral feeding. However, the question is ambiguously worded as it is not 
explicit whether it implies a positive or negative effect on QOL.   For instance, one 
participant (P20) reported that QOL was “much better” but recorded 1 (‘not at all’) on 
the questionnaire. The score of 1 may have been considered by P20 to imply that PEG 
has ‘not at all’ worsened the QOL. Another participant (P13) reported that the PEG tube 
was a “god send” and recorded 4 (‘very much’) on the questionnaire.  Similarly P2 at 3 
months reported “worse” QOL but recorded 4 (‘very much’) on the Likert scale. It is 
therefore unclear whether high scores imply significant improvement or deterioration in 
QOL. Given the vagueness on the relevance of scores, this domain was not analysed in 
this study.   
 
4.14 Quality of life results: A thematic analysis of participants’ perspectives   
The written comments from participants in response to the two open questions “What 
other comments you wish to make about your PEG?” and “How would you describe 
your quality of life since the insertion of your feeding tube?” were subjected to thematic 
analysis, a qualitative mode of methodical inquiry that systematically investigates 
textual data, to identify relevant themes (Braun and Clarke, 2006). 
Due to the distinct lack of literature on the impact of enteral feeding on QOL, it 
appeared essential to identify, analyse and report patterns within the data set to provide 
a set of themes which could inform clinical practice. These themes could also form a 
basis, from which future research can build upon and develop further. Moreover, it was 
essential to employ a flexible, replicable and transparent analytic method.  It was 
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therefore felt that thematic analysis would be the most appropriate methodology for data 
analysis.  
Thematic analysis is a highly flexible approach that provides a rich thematic description 
of the entire data set and is therefore a useful methodology when exploring new or 
under researched areas (Braun and Clarke, 2006).  Finally, thematic analysis does not 
necessitate the detailed theoretical and technological knowledge of other qualitative 
approaches and can therefore, offer a more accessible and transparent form of analysis, 
particularly for those with no previous experience of qualitative research (Braun and 
Clarke, 2006).  
An inductive, semantic and realist approach to thematic analysis was followed in 
accordance with the step-by-step guidelines recommended by Braun and Clarke (2006). 
As the study intended to explore patients’ perspectives about the impact of enteral 
feeding on their QOL, the analysis was data-driven. In this sense, the analysis was 
inductive as the data was coded without any analytic preconceptions. The analysis took 
a semantic approach and themes were identified from the obvious meanings of data 
rather than looking for underlying presumptions (Braun and Clarke, 2006).  A realist 
approach allowed identification and reporting of patients’ perspectives of enteral 
feeding on their QOL.  
During the analysis, the written views of participants were read repeatedly to ensure 
familiarity with the data set.  The focus was on what content the narratives 
communicated. Coding was then undertaken, ascribing each sentence or account a code 
that described the main essence of the narrative. The codes were then assembled into 
more and more abstract codes, incorporating those that were similar in meaning and 
content until they represented a theme.  
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The analysis was an iterative and cyclical process, initially looking for shared themes 
between the sentences and searching for patterns in semantic content. Any substantial 
themes were noted and the data reread in the context of these themes. By immersing 
deeper in the generated themes and the underlying key perceptions, themes deemed 
similar were merged and those encompassing conceptually distinct themes were 
divided. The themes were finally refined and grouped into clusters to form overarching 
themes and subthemes.  Meticulous care was undertaken during the analytical process to 
ensure that the original context of the data was not eroded. 
The thematic analysis resulted in identification of four main themes: No change in 
QOL, worse QOL, improved QOL and problems with enteral feeding. A number of 
subthemes were identified which will be discussed further. The identified themes and 
subthemes are displayed in Figure 4.6. The subthemes are not exclusively distinct but 
remain interrelated to one another.  
There were accounts from 17 participants at 3 months post gastrostomy; 13 participants 
indicated improvement in QOL, 3 reported no change in QOL and 1 reported worse 
QOL. At 6 months post gastrostomy, there were comments from 17 participants;  13 
participants reported improved QOL despite inconveniences associated with enteral 
feeding. No participant reported worsening of QOL.  At 12 months post gastrostomy, 
there were comments from 8 participants of which 1 participant (P1) reported no change 
in QOL, although did note that the gastrostomy tube was an “inconvenience”. No 
participants reported worsening of QOL. For one participant, enteral feeding was “a 
God send” (P13). A number of selected verbatim quotations to illustrate the views and 
perspectives of the participants will be included in the section that follows. Table 4.2 
shows detail individual patient accounts regarding the impact of enteral feeding on their 
QOL at 3, 6 and 12 months following gastrostomy insertion. 
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Figure 4.6: Diagram depicting the main themes and subthemes 
 
 Perceived survival benefit 
 Improved nutrition and hydration 
 
 Relief of anxiety 
 Facilitates travelling 
 More free time 
 Convenient route for medication delivery 
 Weight gain 
             No difference 
       Problems with gastrostomy tube 
Improved QOL 
 
No Change in 
QOL 
 
 Clinical complications 
 Social isolation 
 Loss of pleasure associated with eating 
 Body image 
 Change in attire 
 Handling the tube 
 Anxiety 
 Dependence on others 
 Family conflicts 
  
 Improved nutrition and hydration 
 
 Relief of anxiety 
 Facilitates travelling 
 More free time 
Problems with 
enteral feeding 
Worse QOL 
 
106 
 
4.14.1 Improved QOL 
The vast majority of participants reported improved QOL. Data analysis identified the 
following themes which were associated with improved QOL.  
Perceived survival benefit 
Enteral feeding was perceived as being essential to survival and some participants 
expressed the view that enteral feeding had kept them alive. Enteral feeding was felt to 
have a positive impact not only on quantity but also QOL. These are exemplified in the 
following statements:  
 
 
 
 
 
Some participants had disinclination towards gastrostomy tube, but they acknowledged 
the positive impact of enteral feeding on survival and QOL.  
 
 
 
Improved nutrition and hydration 
Participants felt that their nutritional and hydration needs were met with enteral feeding. 
Their views about improved nutrition were maintained throughout the study period:  
 
 
“It has been a great help. I couldn’t manage without it.” (P3) 
“I'm just so grateful it’s helping me to live, and live more   
comfortably.” (P9)  
“Without it – it would be (RIP).” (P14) 
  
 
“Would rather not have it, but for the purpose it was fitted think it has 
kept me alive for longer and made my quality of life much better.” (P6) 
“On the whole better with PEG than without it. I was not able to get 
enough food or fluid into me by mouth anymore so now feel better.” 
(P5) 
 
 
107 
 
 
 
 
 
Some participants were glad that they considered enteral feeding at an early stage as 
they no longer had to struggle at meal times with choking or coughing: 
 
 
 
 
Relief of anxiety  
A number of participants reported that enteral feeding had helped to alleviate their 
anxieties about the inability to eat or drink. Participants did not have to “worry” about 
nutrition (P2, P5, P11, P13, P17 and P6) and hydration (P9, P17 and P20).  
  
 
 
 
 
“I'm glad I had it inserted early, it’s been so useful in ensuring that I 
could have sufficient fluids and  medication daily and recently I have 
used it to take fortisips as my ability to swallow has weakened also, I 
do not have to cough or choke any more when using the PEG instead 
of oral intake.” (P9) 
 
 
“My quality of life has changed for the better. Improved, I am not 
hungry or thirsty and don’t have to struggle to swallow.” (P8) 
 “Quality of life has improved greatly. Without it I could not get any 
nutrition!.” (P11) 
 
 
“The PEG has not stopped me from doing anything. It is not difficult 
to use and is easy to maintain. It has taken the stress out of eating and 
drinking.” (P5) 
“Much improved as I can now have sufficient fluid without worrying 
about dehydration.” (P9) 
“It means I don't have to worry about getting nutrients and calories 
into my system. It gives me more energy. Thanks.”  (P11) 
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Some participants felt that enteral feeding was brilliant. It helped to removing the 
‘stress’ of eating and they would recommend it to other patients needing it: 
 
 
Participants felt that enteral feeding was a source of relief not only for themselves but 
also for their family members: 
 
 
 
A change in QOL may not be noticed in the first few postprocedural months. P16 had 
reported no change in QOL at 3 months but this view changed at 6 months: 
 
 
 
Similarly P2 noticed improved QOL at 12 months despite reporting worse QOL at 3 
months: 
 
 
“I think they are brilliant.... Took stress off me eating. It has made my 
quality of life so much better I would recommend it.” (P10) 
 
“Quality of life is much better for me and my family since PEG fitted, 
I know I am getting all my dietary needs and my family know I am 
which is relief for all.” (P6) 
 
 
 “Glad that I had it done, swallowing is becoming more and more 
difficult and I am choking more.” (P16) 
 
 
“My quality of life is better. I do not worry about food.” (P2 at 12 
months) 
 
“Much better, such a relief to be able to take liquid which because of 
my swallowing difficulties I can’t manage otherwise…… No trouble at 
all using it and thankful for it.” (P20)  
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Facilitates travelling 
Enteral feeding can give patients the freedom to travel without fear of prolonged meal 
times. Patients also adjust to the notion of administering feeds through the gastrostomy 
tube, even in presence of other people:  
 
 
 
 
More free time  
Dysphagia is associated with prolonged meal times and can be tiring for patients. 
Enteral feeding can help to reduce the cumbersome meal times: 
 
 
 
Enteral feeding also helped to save “time and energy”.  
 
 
 
 
Convenient route for medication delivery  
Gastrostomy tube can be a helpful alternative route for delivery of medicines. Patients 
do not have to struggle to swallow tablets and it can also help delivery of medications, if 
hospital admission is required. Delivery of medicines through the gastrostomy tube 
“My quality of life has improved it has made travelling better as I can 
take my own supplies. Putting a feed in by tube is much quicker than 
the speed I was eating before. I am no longer shy of people seeing me 
put a feed in so I can go anywhere I want to go.” (P5)  
 
 
“Since having my PEG tube fitted I have found my life has become a 
lot easier. At first it took a lot of getting used to. Having a PEG has 
freed up a lot of my time.” (P19) 
 
 “It has removed the pressure. Although I have only used it for bolus 
feeds once a day. That has helped enormously saving time and 
energy.” (P13) 
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enabled one participant to avoid the unpleasant taste of some of the medicines. All these 
factors may have a positive impact on QOL: 
 
 
 
 
 
Although patients may find the need for gastrostomy tube upsetting, they appreciate the 
benefits associated with gastrostomy tube feeding:  
 
Weight Gain 
One participant reported improvement in QOL and attributed this to weight gain.    
 
 
4.14.2 No change in QOL 
Some participants (P1, P7 and P16) reported no changes in their QOL at 3 months:  
 
  
Despite no perceived change in QOL, one participant found the presence of gastrostomy 
tube reassuring:  
 
“Much better, weight gained.” (P6) 
 
 
“Better for taking meds poorer for needing it.” (P21) 
 
 
 
 
“I don't really think about it. It hasn't really changed my quality of 
life” (P16) 
 
 
 
 
“Just as same as before; been a good thing, a reassurance” (P1) 
 
 
“Better, I can take medication via the tube, saves swallowing.” (P21)  
“I am currently in hospital so the nurses are giving me feeds. It has 
made it easier for me to take medication.” (P16) 
“A lot more pleasant now, bad tasting medication goes down the   
tube.” (P19) 
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At 6 months, three patients (P1, P2, and P7) reported no change in QOL. P1 however, 
felt that it provided “assurance as  backup”.  At 12 months, only P1 reported no change 
in QOL. Despite the inconveniences, it was still a reassurance:  
 
 
P7 was not using the gastrostomy tube at 3 and 6 months and therefore may not have 
noted any difference in QOL. P7 did not provide any comments at 12 months follow up 
but indicated in the Liverpool PEG questionnaire that it had not affected the overall 
QOL. Participants P2 and P16 however, reported improved QOL at subsequent follow 
up evaluation, as described in the foregoing section on improved QOL.   
 
4.14.3 Worse QOL 
Percutaneous gastrostomy tube can be associated with complications including wound 
infection and pain. These complications can negatively affect patient’s QOL. One 
participant (P2) reported worse QOL at 3 months post gastrostomy due to problems 
with the gastrostomy tube. However improved QOL was reported in subsequent visits 
following successful management of infection and pain.  Despite the complications, 
gastrostomy tube can be a source of hope for the future: 
 
 
4.14.4 Problems with enteral feeding  
Enteral nutrition via a gastrostomy tube can be associated with a number of problems 
including tube leakage, pain and bleeding. Some patients are fully reliant on their 
“To be honest, irritating to have to flush it daily but realise it is there 
as a vital back up to be used if and when required.” (P1) 
 
 
 
“Quality of life worse due to infection + pain. However, I do not 
regret having it done as I know I will need it in the future.” (P2) 
”. 
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families/relatives for help with delivery of feeds. The following problems were 
identified from the comments provided by the study participants.  
Clinical complications 
Participants had an uneventful recovery following gastrostomy insertion and did not 
experience any major complications. However, minor complications including pain, 
infection and tube leakage were experienced, mainly in the first 3 months following 
gastrostomy insertion.  These complications could potentially have a negative impact on 
the QOL of patients:  
 
 
 
 
 
One participant reported upper gastrointestinal bleeding: 
 
 
 
 
 
Social isolation  
Enteral feeding can prevent patients from socialising with friends and/or families. 
Despite this drawback, enteral feeding can still have a positive impact on QOL: 
“Quality of life worse due to infection + pain.” (P2 at 3 months)  
“It’s the irritation from the disk digging into my skin - It pushes the 
skin off and its constantly sore.” (P11 at 3 months) 
“Sore for 1st 2 weeks.” (P17 at 3 months) 
“It bleeds and leaks quite a bit.” (P21 at 3 months) 
 
 
 
“… a duodenal ulcer bleed. Possible cause me producing too much 
stomach acid for the change in food type – rushed into hospital – had 
drips for a few days and a couple of bags of blood – (still 8 in 
credit).” (P14) 
 
 
 
113 
 
 
 
 
 
 
 
 
Altering the feeding times with the majority of feeds being delivered at night can reduce 
the negative impact on social life. One participant came up with a solution to reduce the 
impact of enteral feeding on social life: 
 
 
 
Loss of pleasure associated with eating 
Eating is associated with a number of pleasurable themes including taste and smell. 
Enteral feeding can lead to loss of pleasure associated with eating:  
 
 
 
 
 
 
“….it prevents me from eating out with friends or going out for a 
whole day. But I get round that as my friends understand and as the 
PEG so is so discreet when not in use I'm just so grateful its helping 
me to live and live more comfortably.” (P9) 
“To begin with had to organise the social life around the PEG feeds 
or take a big bag with me. Now only needs one top up during day. Life 
has greatly improved before I was always choking when eating food 
even mashed up food.” (P19) 
 
 
 
“Since going to all night feeding + top up, the feeding has become 
less of a trial. Before needed to feed every 4 hours it affected our 
social life and general life.” (P19) 
 
 
 
“At first longed for food (Real food, I dream of roast beef and fish and 
chips). Not really missing eating food. As I know there is no chance of 
being hospitalised due to choking. Only downside is getting used to 
feeling full and not taking anything in my mouth or down my throat.” 
(P19) 
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Body image 
The location of the gastrostomy tube can lead to perception of uneasiness about the 
body image:  
 
 
 
 
Change in attire 
Participants also had to adjust their attire to accommodate for the gastrostomy tube: 
 
Handling the tube 
Maintaining the tube hygiene and preventing it from blockage, when not in use, can be a 
source of irritation to patients:  
 
 
Patients may also struggle using the syringes to aid delivery of nutrition through the 
gastrostomy tube: 
 
 
 
 
“It dangles where other things dangle. The problems seem to be 
associated with its location, just under my prominent breastbone.” 
(P21) 
 
 
 
 
“Need to wear clothes with large elastic waist.” (P17) 
 
 
 
 
“To be honest, irritating to have to flush it daily but realise that it is 
there as a vital back up to be used if and when required.” (P1) 
 
 
 
 
“Of course, using the PEG takes longer sometimes than normal 
feeding + taking medication  as I have to use syringes, and other 
preparations. Most tiresome is having to take Fibre Fortisip which 
requires a plunger, and is difficult with weakening fingers and 
wrists.” (P9) 
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Anxiety 
Living with a feeding tube can be a source of anxiety for patients. One participant was 
anxious about potential tube blockage: 
 
 
 
Dependence on others 
Some participants (P2, P8, P14 and P21) were dependent on their family or carers for 
help with enteral feeding or maintenance of tube hygiene.  
 
 
 
 
 
Participants also indicated dependence on things they expressed as being out of their 
control: 
 
 
The role of family members in helping with enteral feeding and thereby enhancing QOL 
of patients cannot however be understated: 
 
 
“I worry about it getting blocked. I wonder if someone will invent a 
‘brush’ to ensure that it can be cleaned so that it will not block.” (P2) 
 
 
 
“My husband helps me with my feeds and cleaning and turning the 
tube. I definitely needed to have it.” (P8) 
“My carer dresses the PEG site every day because of leakage.” (P21) 
 
 
 
“If I had not got a loving and caring wife I would be in difficulties. 
She sorts out all medications, feeds, and with her ability to get on with 
everybody (despite having bad knees) we get on great.” (P14) 
 
 
 
“I feel I have to use gauze around the tube after showering as carers 
do not dry the area properly.” (P2) 
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 Family Conflicts 
Dependence on others for instance, family members, can be a source of potential 
conflict: 
 
 
 
Despite all the inconveniences, patients have a positive attitude towards enteral feeding: 
 
 
 
 
“…my children have to give medication + feeds via the tube which 
causes anxiety + arguments.” (P2) 
 
 
 
 
“I am grateful that the PEG offers an alternative way of nourishing 
myself, and whatever inconveniences I may have are greatly 
outweighed by the advantages” (P9) 
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Table 4.2: Table showing individual patient accounts regarding the impact of enteral feeding on their QOL at 3, 6 and 12 months following 
gastrostomy insertion  
 
Patient 
Number 
3 months 6 months 12 months 
1 Just the same as before; been a good thing, 
a reassurance.  
No difference but provides assurance as 
back up. 
To be honest, irritating to have to flush it 
daily but realise it is there as a vital 
backup to be used if and when required. 
No inconvenience. 
2 Quality of life worse due to infection + 
pain. However, I do not regret having it 
done as I know I will need it in the future.  
Not really any different though my 
children have to give medication + feeds 
via the tube which causes anxiety + 
arguments. 
 
I feel I have to use gauze around the tube 
after showering as carers do not dry the 
area properly 
My quality of life is better. I do not worry 
about food.  
 
I worry about it getting blocked. I wonder 
if someone will invent a ‘brush’ to ensure 
it can be cleared so it will not block. 
3 It has been a great help. I couldn’t manage 
without it 
RIP  RIP 
4 RIP RIP RIP 
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5 The PEG has not stopped me from doing 
anything. It is not difficult to use and is 
easy to maintain. It has taken the stress out 
of eating and drinking.” 
On the whole better with PEG than 
without it. I was not able to get enough 
food or fluid into me by mouth anymore 
so now feel better. 
 
My quality of life has improved it has 
made travelling better as I can take my 
own supplies. Putting a feed in by tube is 
much quicker than the speed I was eating 
before. I am no longer shy of people 
seeing me put a feed in so I can go 
anywhere I want to go. 
Moved out of area 
6 Much better, weight gained Would rather not have it, but for the 
purpose it was fitted think it has kept me 
alive for longer and made my quality of 
life much better. 
Quality of life is much better for me and 
my family since PEG fitted, I know I am 
getting all my dietary needs and my 
family know I am which is relief for all. 
RIP 
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7 
 
No change  
 
No difference 
 
No comments 
 
8 My quality of life has changed for the 
better 
Improved, I am not hungry or thirsty and 
don’t have to struggle to swallow. 
 
My husband helps me with my feeds and 
cleaning and turning the tube. I definitely 
needed to have it. 
RIP 
9 Much improved as I can now have 
sufficient fluid without worrying about 
dehydration. 
I'm glad I had it inserted early, it’s been so 
useful in ensuring that I could have 
sufficient fluids and  medication daily and 
recently I have used it to take fortisips as 
my ability to swallow has weakened also, 
I do not have to cough or choke any more 
when using the PEG instead of oral intake. 
 
Swings + roundabouts. On the upside are 
the comments above, on the downside it 
prevents me from eating out with friends 
or going out for a whole day. But I get 
I am grateful that the PEG offers an 
alternative way of nourishing myself, and 
whatever inconveniences I may have are 
greatly outweighed by the advantages. 
 
Of course, using the PEG takes longer 
sometimes than normal feeding + taking 
medication as I have to use syringes, and 
other preparations. Most tiresome is 
having to take Fibre Fortisip which 
requires a plunger, and is difficult with 
weakening fingers and wrists. 
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round that as my friends understand and as 
the PEG so is so discreet when not in use 
I'm just so grateful it’s helping me to live, 
and live more comfortably.” 
10 Better made me get an appetite. I think they are brilliant  Took stress off me eating. It has made my 
quality of life so much better I would 
recommend it 
11 It means I don't have to worry about 
getting nutrients and calories into my 
system. It gives me more energy. Thanks. 
 
It’s the irritation from the disk digging 
into my skin - It pushes the skin off and its 
constantly sore 
Quality of life has improved greatly. 
Without it I could not get any nutrition! 
No comments 
 
12 
 
Withdrew from the study 
 
Withdrew from the study 
 
Withdrew from the study 
 
13 It has removed the pressure. Although I 
have only used it for bolus feeds once a 
day. That has helped enormously saving 
time and energy. 
Mainly beneficial  It’s a godsend. Didn’t think about after a 
few months, aware of it at the beginning. 
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14 Apart from a duodenal ulcer bleed. 
Possible cause me producing too much 
stomach acid for the change in food type – 
rushed into hospital – had drips for a few 
days and a couple of bags so blood – (still 
8 in credit). 
Without it – it would be (RIP). If I had not 
got a loving and caring wife I would be in 
difficulties. She sorts out all medications, 
feeds, and with her ability to get on with 
everybody (despite having bad knees) we 
get on great. 
Wouldn’t be here if I had not got it. 
A well thought of idea. 
 
15 
 
RIP 
 
RIP 
 
RIP 
 
16 I don't really think about it. It hasn't really 
changed my quality of life. 
Glad that I had it done, swallowing is 
becoming more and more difficult and I 
am choking more. 
 
I am currently in hospital so the nurses are 
giving me feeds. It has made it easier for 
me to take medication. 
RIP 
17 Much better – eating food/drinking liquid 
was making me choke and cough. 
 
Sore for 1
st
 2 weeks 
Need to wear clothes with large elastic 
waist. 
Withdrew from the study 
 
18 
 
No comments 
 
Good 
 
RIP 
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19 Forget PEG is even there.  
 
Quality of life easier with PEG. No fear of 
choking not like trying to swallow real 
food. A lot more pleasant now, bad tasting 
medication goes down the tube. Only 
downside is, could be lazy, easier to get 
nutrition from PEG feeding rather than 
struggling to swallow. 
To begin with had to organise the social 
life around the PEG feeds or take a big 
bag with me. Now only needs one top up 
during day. Life has greatly improved 
before I was always choking when eating 
food even mashed up food. 
 
Since going to all night feeding + top up, 
the feeding has become less of a trial. 
Before needed to feed every 4 hours it 
affected our social life and general life. 
 
At first longed for food (Real food, I 
dream of roast beef and fish and chips). 
Not really missing eating food. As I know 
there is no chance of being hospitalised 
due to choking. Only downside is getting 
used to feeling full and not taking 
anything in my mouth or down my throat. 
 
Since having my PEG tube fitted I have 
found my life has become a lot easier. At 
first it took a lot of getting used to. Having 
a PEG has freed up a lot of my time. I 
found all night feeding was much better 
than feeding every four hours which I 
found took up a lot of my time.  
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20 Much better, such a relief to be able to 
take liquid which because of my 
swallowing difficulties I can’t manage 
otherwise. Also being able to take Fortisip 
as a back up. No trouble at all using it and 
thankful for it 
Much better RIP 
21 Better, I can take medication via the tube, 
saves swallowing. The problems seem to 
be associated with its location, just under 
my prominent breastbone. But I’m not 
looking forward to when it’s the only 
method of feeding that I have.  
 
It dangles where other things dangle.  
 
The cap at the end is difficult to remove. 
 
Its location leads to problems, it’s very 
prominent.  
 
It bleeds and leaks quite a bit.  
Better for taking meds poorer for needing 
it. 
 
My carer dresses the PEG site every day 
because of leakage 
Beneficial for taking pills which I was 
struggling to take. 
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4.14 Discussion 
Quality of life (QOL) is conceptually an ill-defined term due to its holistic and 
subjective dimension and means different things to different people (Fayers and 
Machin, 2007; Rapley, 2003). Despite its subjective nature, the views and perspectives 
of patients about the impact of any treatment on their QOL adds another dimension to 
the evaluation of treatment (Good et al., 2014).  
Although enteral feeding is routinely offered to patients with MND, there is no evidence 
to support or refute enteral feeding for maintaining or improving QOL. This prospective 
study is the first of its kind in the literature to demonstrate that enteral feeding helps to 
maintain or enhance QOL of patients. 
Placement of a gastrostomy feeding tube has fundamental ethical issues and the 
decision to offer gastrostomy should depend on whether a patient will derive any actual 
benefit from it (Good et al., 2014). The needs, expectations, views and wishes of 
patients are of paramount importance and treatment efforts should be focussed at 
improving quality rather than just quantity of life (Bozzetti, 2008).  
Eating is associated with a number of non-nutritional but pleasurable themes including 
taste, smell and socialization (Bozzetti, 2008; Brotherton and Judd, 2007; Roberge et 
al., 2000). Eating food with others helps to foster social and familial relationships and is 
related to a feeling of general wellbeing (Spataro et al., 2011).  Enteral feeding, 
however, removes all these themes, thereby depriving the patient of the social role of a 
meal (Bozzetti, 2008; Brotherton and Judd, 2007; Roberge et al., 2000). Moreover, 
enteral feeding is not without complications. It can, thus, be speculated that the 
psychosocial inconveniences and difficulties with enteral feeding has a significant 
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impact on QOL of patients.  Assessing QOL is, therefore, important to optimize the 
adequacy of enteral feeding to the needs and expectations of every individual patient. 
This study was designed mainly to evaluate the effect of enteral feeding on QOL of 
patients with MND. The progressive deterioration in the ALSFRS-R and ALSAQ-40 
scores are in keeping with the natural history of the condition (Cedarbaum et al., 1999; 
Jenkinson et al., 2003; Kaufmann et al., 2005; Norquist et al., 2004). Interestingly, the 
mean emotional functioning sub scores of ALSAQ-40 remained relatively constant 
following enteral feeding, as opposed to all other domains which increased with time. 
This interesting finding indicates that enteral feeding ameliorates emotional problems, 
for instance, feeling lonely, bored, and depressed or worry about how the disease will 
affect them in the future. The thematic analysis has given valuable insights into 
patients’ perspectives of enteral feeding and its impact on their QOL.  
The vast majority of participants had a positive attitude towards enteral feeding. Enteral 
feeding was perceived as being essential to survival by some patients while others felt 
that it helped to facilitate travelling, gain weight and save time and energy. Participants 
also reported a sense of relief and security that their nutritional needs were met. The 
BMI stabilised following gastrostomy and some participants felt that this had a positive 
impact on their QOL. Malnutrition and weight loss can significantly impact QOL, as 
patients are often exhausted, tired and spiritless (Greenwood, 2013; Korner et al., 2013). 
The findings of this study strongly indicate that management of malnutrition can play an 
important role in either maintaining or enhancing QOL. 
Gastrostomy tube was associated with a number of complications including pain, 
leakage and infection.  Despite the complications, participants had no regrets with 
gastrostomy as they see it as a “vital back up to be used if and when required”. Enteral 
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feeding caused conflicts among family members and also led to loss of ability to share a 
meal and socialise with friends/families. These experiences can potentially lead to social 
isolation and anxiety/depression. Moreover, placement of feeding tube is associated 
with a multitude of emotions and adaptations.  It is, therefore, important for health care 
professionals to understand these consequences of enteral feeding, monitor for signs of 
anxiety/depression, educate family members involved in the patient’s care, and help 
patients and families to develop effective coping strategies.   
Despite the inconveniences associated with enteral feeding, the reported positive 
benefits outweigh the negative aspects of enteral feeding.  Only one participant reported 
worse QOL at 3 months post gastrostomy. However, this view changed at 12 months 
post gastrostomy and there was a perception of improved QOL. Finally, at 12 months 
follow up, none wished for the feeding tube to be removed, indicating a positive attitude 
towards enteral feeding.  
Only 11.1% (n=2) and 17.7% (n=3) wished for the gastrostomy tube to be removed at 3 
and 6 months, respectively. It is noteworthy that none wished ‘very much’ for the tube 
to be removed at any point. This is in contrast to a study involving 39 patients with head 
and neck cancers where 69% of the patients wished to have the feeding tube removed 
(Roberge et al., 2000). However, 80% of the patients were fed through nasogastric tube 
and the evaluation was undertaken at 7 days following discharge. Nasogastric tube 
feeding is often poorly tolerated (Heffernan et al., 2004; Scott and Austin, 1994) and 
this coupled with early evaluation may explain the high percentage of patients longing 
to have the tube removed.   
The first few months following gastrostomy can be very challenging for patients who 
may encounter clinical and non-clinical problems associated with enteral feeding. 
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However, with passage of time, patients appear to cope well with the inconveniences 
and appreciate the positive impact of enteral feeding on their QOL. The positive impact 
may therefore not be noticed within the first few months after gastrostomy. A similar 
observation has been made by Bannerman et al. (2000) in a study evaluating the impact 
of enteral feeding on patients with dysphagia due to a range of causes. The authors 
reported an overall positive impact of gastrostomy on QOL among 55% patients at 1 
month, 71% at 6 months and 75% at 12 months (Bannerman et al., 2000).  
Percutaneous gastrostomy is a safe procedure associated with low risk of complications. 
The 30 day mortality following gastrostomy in MND ranges from 2 – 25% (Chio et al., 
1999; Desport et al., 2000; Forbes et al., 2004; Mathus-Vliegen et al., 1994; Mazzini et 
al., 1995). This is similar to the 30 day mortality of 8 – 28% following gastrostomy 
insertion in an unselected patient population including a range of neurological disorders 
and tumours of the head, neck and gastrointestinal system (Blomberg et al., 2012).  In 
the current study, there were no deaths within 30 days of gastrostomy insertion. 
The two most common complications in this study were redness/irritation and tube 
leakage occurring in up to 70% and 60% of the cases, respectively. The clinical 
complications were similar to those observed in unselected patient population receiving 
gastrostomy for a number of tumours and neurological conditions, where tube leakage 
and peristomal infection occurred in 78% and 53% of the patients, respectively 
(Blomberg et al., 2012; Potack and Chokhavatia, 2008; Rogers et al., 2007). Infection 
was less common in the current study and was reported by only a quarter of the 
participants, which may reflect improvement in standards of infection prevention.    
There is little in the published literature on the impact of enteral feeding on QOL of 
MND patients. The literature review identified only 4 studies on the topic. Three of 
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these (Lou et al., 2010; Mitsumoto et al., 2003; Zamietra et al., 2012) provide 
retrospective data from studies that were not primarily intended to investigate the 
association between enteral feeding and QOL. The only prospective study by Mazzini et 
al. (1995) provides anecdotal impressions from patients about their improved QOL but 
the authors do not present any concrete data relating to their observations.   
Lou et al. (2010) reported a statistically significant reduction (P <0.001) in the rate of 
decline on the MQOL-SIS, suggesting that enteral feeding improves QOL. The authors 
compared the slopes of MQOL-SIS, before and after gastrostomy insertion of 52 
patients receiving PEG tube.  Zamietra et al. (2012), retrospectively, reviewed the QOL 
scores, measured by using the ALSSQOL-R scale of 11 patients who had received PEG 
tube. Although the QOL scores deteriorated marginally over time, the difference was 
not statistically significant.  
In a retrospective study, 28% listed less fatigue or less time spent on meals and 17% 
listed improved psychological wellbeing as positive effects of enteral feeding 
(Mitsumoto et al., 2003). Patients with enteral feeding experienced a significant 
(p=0.0047) poorer health status on the mini-sickness impact profile scale as compared 
to patients without enteral feeding. However, the bulbar sub scores were significantly 
lower in the gastrostomy group (p<0.0001) indicating that gastrostomy was performed 
too late to demonstrate a positive impact on QOL.  
It is interesting to note that even outside the field of MND, the impact of enteral feeding 
on QOL remains a topic of debate (Good et al., 2014).  A recent systematic review 
aimed at assessing the impact of medically assisted nutrition on the QOL of palliative 
care patients including cancer, dementia and neurodegenerative conditions did not 
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identify any randomised controlled trials or prospective non-controlled studies on the 
topic (Good et al., 2014).   
Prospective studies of enteral feeding delivered through gastrostomy tube in patients 
with cancer (mainly head and neck) and neurological disorders (mainly stroke) has 
demonstrated maintenance or even improvement in QOL of patients, particularly in 
those without cancer (Klose et al., 2003; Schneider et al., 2000; Senft et al., 1993). 
Enteral feeding was associated with personal independence and improved physical and 
mental wellbeing (Schneider et al., 2000; Verhoef and Van Rosendaal, 2001).  
Other studies in head and neck cancer, on the contrary, report negative psychosocial 
implications of enteral feeding including interference with family life, intimate 
relationship and social activities (Roberge et al., 2000; Rogers et al., 2007). About 50% 
of patients feel socially excluded due to the loss of social function of eating (Bannerman 
et al., 2000). In another study involving 20 patients with a wide range of neurological 
conditions and cancer, patients felt that tube feeding finally came to dominate their lives 
and was associated with an appreciable burden of treatment (Jordan et al., 2006). 
However, 17 out of 20 participants had experienced serious technical problems with 
their gastrostomy tubes which could have contributed to the ‘burden of treatment’.  
These studies, therefore, report a variable impact of enteral feeding on QOL. The 
conflicting results may be due to a number of variable factors including the 
heterogeneous population in terms of underlying primary diagnoses. Moreover, the 
studies have used different measuring instruments that generate results which cannot be 
meaningfully compared. However, these studies clearly paint a common picture – 
enteral feeding has an impact on QOL of patients. The expected benefits, risks and 
burden to the QOL should therefore be carefully considered and discussed with the 
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patient and the family to help ensure that all decisions about enteral feeding are 
informed and appropriate.  
Although 17 patients completed the study, the sample size is felt to be appropriate as no 
additional themes were emerging and data saturation was therefore achieved. The data 
can also be deemed as robust and complete as almost all surviving participants 
completed the study.  Strengths of this study include the prospective design and the 
completeness of inclusion and follow-up. Despite being a single site study, the subjects 
in this investigation are representative of the MND population requiring enteral feeding 
and the findings may therefore be transferable to other MND patient cohorts.  
 
4.16 Conclusion 
This work is the first study of its kind in the United Kingdom to demonstrate the 
positive impact of enteral feeding on QOL of patients with MND.  The study offers 
support for the use of enteral feeding in improving or maintaining QOL of MND 
patients. A major theme that has surfaced from the study is that the available QOL 
instruments do not provide specific information regarding the impact of enteral feeding 
on an individual patient’s QOL. There is a need to develop measurement tools that will 
mirror the QOL of MND patients receiving enteral feeding.  Such tools should also take 
into account the emotional impact of the disease itself, which has a fatal prognosis.  
Placement of a gastrostomy tube for enteral feeding requires careful individualisation 
based on the needs, expectations, views and wishes of the patient and its impact on their 
QOL. This study provides rich narratives from MND patients regarding their 
perceptions of enteral feeding. A key finding relevant for clinical practice is that most 
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study subjects acknowledged the importance of feeding tube and hence, the positive 
perception of enteral feeding.  
In conclusion, the positive impact of enteral feeding on QOL and the themes that have 
surfaced from this research assuredly require further studies. The described themes 
provide important descriptions of the emotional, psychological and social impact of 
enteral feeding and can serve as a starting point for other prospective studies on the 
topic. This understanding is crucial for providing patients with evidence-based 
counselling on nutritional management and identifying areas for interventions aimed at 
maximizing the QOL benefit of enteral feeding. 
 
 
. 
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CHAPTER 5 
 
 
 
 
GENERAL DISCUSSION 
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5.1 Preview to the Discussion 
This thesis consisted of a programme of work which investigated the outcomes of 
enteral feeding and clinico-demographic characteristics of MND in Lancashire and 
South Cumbria in North West England. This final chapter presents a synopsis of the 
thesis and describes the key findings of the work.  Conclusions are drawn within the 
context of limitations and recommendations for future research and practice proposed. 
 
5.2 Overview of the thesis  
Motor neurone disease is a fatal neurodegenerative disease of unknown aetiology, 
associated with the degeneration of upper and lower motor neurones (Hardiman, 2000; 
Miller et al., 2009). The clinical course is characterised by relentlessly progressive 
wasting and weakness of skeletal muscles leading to respiratory failure and death.  The 
median survival from symptom onset to death varies from 20 to 48 months (Beghi et al., 
2011). In the absence of a cure, supportive and palliative treatments remain the 
mainstay of management (Bede et al., 2011).  Palliative and supportive management 
should start early as disability is unremittingly progressive and death generally occurs in 
a predictable fashion (Bede et al., 2011; Mitsumoto et al., 2005).   
The main goal of treatment in MND is either to maintain or enhance QOL of patients 
through understanding and identification of their physical, psychological and social 
needs (Simmons, 2005). Health care professionals should therefore have a good 
understanding of the concept of QOL and how it is measured.  The clinician caring for 
MND patients therefore encounters not only extraordinary challenges, but also 
extraordinary opportunities in providing expert care throughout the trajectory of this 
cruel and devastating illness.  
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Malnutrition is an independent prognostic factor for survival in MND (Desport et al., 
1999; Marin et al., 2011). Malnutrition and weight loss negatively impacts QOL and 
patients feel exhausted, tired and spiritless, irrespective of the stage of illness 
(Greenwood, 2013; Korner et al., 2013). The requirement for enteral feeding eventually 
becomes a common occurrence in a significant proportion of patients with MND 
(Strong et al., 1999). Although enteral nutrition is offered to patients with dysphagia 
and/or weight loss, its effect on various outcomes including survival and QOL remains 
an issue of debate (Katzberg and Benatar, 2011; Miller et al., 2009). 
This thesis was originally designed to assess the impact of enteral feeding on survival, 
nutritional status and QOL of patients with MND. The thesis also intended to describe 
the demographic and clinical characteristics of MND in Lancashire and South Cumbria 
in North West England.  
Chapter 1 provided a background to the thesis. The chapter began with a discussion on 
the history and nomenclature of MND. Key concepts including epidemiology, aetio-
pathogenesis, clinical characteristics, diagnosis and management of MND were 
reviewed, highlighting the phenotypic, genetic and prognostic heterogeneity.  The 
concept of malnutrition as an independent prognostic factor for worsened survival was 
then introduced, thereby setting the scene for use of enteral feeding in MND.   
Chapter 2 presented a systematic review assessing the impact of enteral feeding on 
survival, nutritional status and QOL of patients with MND. The majority of identified 
studies were retrospective and there were no randomised or quasi-randomised controlled 
trials. The systematic review demonstrated that the evidence for survival advantage with 
enteral feeding is inconclusive and a subject of debate. Although some studies 
suggested survival advantage, many others have failed to support these findings.  There 
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is weak evidence to suggest stabilization of body weight with enteral feeding. There is a 
distinct lack of literature to support or refute enteral feeding for improving QOL.  
Chapter 3 reported the demographic and clinical characteristics of MND in Lancashire 
and South Cumbria in North West England.  The crude incidence rate of MND in the 
study population was 3.15/100,000. There was a slight male preponderance. The overall 
mean age of onset was 67.28 years (S.D. 11.06; range 22.78-93.06 years). The 
presentation was limb/spinal in 62.1% and bulbar in 37.9% cases.  Median overall 
illness duration was 1.98 years (range 1.18-3.05 years). 91 patients received enteral 
feeding of which 67.0% were bulbar onset.  Enteral feeding was not associated with 
survival advantage. 
Chapter 4 investigated the impact of enteral feeding on QOL by exploring the   
perspectives of patients with MND regarding enteral feeding.  The chapter provides rich 
data describing the views and experiences of patients with enteral feeding and its impact 
on their QOL. The results are also discussed in the broader context of extant literature 
on QOL. 
 
5.3 Impact of enteral feeding on survival 
The retrospective study investigating the demographic and clinical characteristics of 
MND in Lancashire and South Cumbria did not demonstrate any survival advantage 
from enteral feeding. This finding is consistent with a majority of other population 
based studies (Atassi et al., 2011; Desport et al., 2000; Forbes et al., 2004; Mathus-
Vliegen et al., 1994; Mitchell et al., 2006; Mitsumoto et al., 2003; Murphy et al., 2008; 
Sorenson et al., 2007; Strong et al., 1999; Zhang et al., 2012). However, the finding 
contradicts with the outcomes of few other studies that suggest survival advantage with 
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enteral feeding (Chio et al., 1999; Chio et al., 2006; Czaplinski et al., 2006; Mazzini et 
al., 1995; Spataro et al., 2011).  
All studies of enteral nutrition in MND have been observational in nature. Therefore, it 
is difficult to be certain whether the discordant impact on survival is due to different 
study designs, discrepancy in the rate of enteral feeding among various centres, bias or 
random error.  
Most studies evaluating the survival outcomes of enteral nutrition were principally not 
designed to determine the effectiveness of enteral feeding as a therapeutic intervention. 
Some studies reported positive survival outcomes from retrospective database analysis 
of patients who had participated in MND drug trials (Kasarskis et al., 1999). However, 
patients enrolled in clinical trials are demographically and clinically different from the 
epidemiologic cohorts as they are usually younger and have spinal onset of the illness 
(Chio et al., 2011b). The findings from these studies therefore lack external validity 
(Chio et al., 2011b). 
There is marked heterogeneity in the rate of enteral feeding among various centres 
caring for patients with MND. In a multicentre study in the United States, only 41% of 
MND patients with dysphagia underwent feeding tube insertion (Mitsumoto et al., 
2003). There was a striking variation in the use of enteral feeding among the nine MND 
centres that participated in this study. The rates of enteral feeding ranged from 0% to 
63% in the various participating clinics (Mitsumoto et al., 2003). In another study in 
northern Italy, 75% of dysphagic patients underwent gastrostomy for enteral feeding 
(Chio et al., 1999).  
A number of factors may explain the variability in the rate of gastrostomy tube insertion 
including criteria for gastrostomy, acceptance rate of gastrostomy by patients, cultural 
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issues and physician bias.  In the multicentre study by Mitsumoto et al. (2003), the 
criteria for gastrostomy insertion was stringent. Dysphagic patients were offered 
gastrostomy only when their ALSFRS-R bulbar sub score was less than 5, out of a 
possible total of 12 (Mitsumoto et al., 2003). Other studies have used less stringent 
criteria and feeding tube insertion was performed at higher bulbar subscores (Chio et al., 
1999; Spataro et al., 2011). This may partly explain why the study by Mitsumoto et al. 
(2003) did not demonstrate survival advantage as compared to the studies by Chio et al. 
(1999) and Spataro et al. (2011). 
Although some evidence can be assembled from these studies, the introduction of bias 
from self-selection of patients for gastrostomy may also influence survival outcomes. 
Some patients opt for gastrostomy whilst others either defer or refuse the procedure 
(Mitsumoto et al., 2003). There is often a tendency by patients to defer gastrostomy 
until they lose a significant amount of bulbar function and severe impairment of 
swallowing becomes a major issue (Mitsumoto et al., 2003).  
The acceptance rate of gastrostomy is also variable across studies reporting survival 
outcomes. In a study carried out in Northern Italy, 75% of MND with dysphagia 
accepted gastrostomy (Chio et al., 1999). However, in another study from Southern 
Italy, only 50.6% accepted the procedure (Spataro et al., 2011). The reasons for these 
incongruities are unclear and it has been suggested that cultural factors may influence 
the rate of gastrostomy acceptance (Spataro et al., 2011).  The variability in timing of 
gastrostomy insertion and self-selection bias may offer another explanation for the 
conflicting impact of enteral nutrition on survival.  
Physician bias and availability of resources are other reasons for variability in 
gastrostomy use (Mitsumoto et al., 2003; Stavroulakis et al., 2013). In a survey of 
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Neurologists from MND Centres in United Kingdom, no Neurologist had the view that 
gastrostomy should be offered soon after diagnosis (Stavroulakis et al., 2013). Objective 
measures such as declining BMI and weight loss were the least used indicators in 
making decisions about enteral feeding. Only 73.7% of the Neurologists indicated 
offering gastrostomy when the BMI drops to less than 18.5 Kg/m
2
. Patient reported 
factors including prolonged and difficult mealtimes were considered more important in 
the decision making process (Stavroulakis et al., 2013). This is surprising, given the 
robust evidence that malnutrition is an independent risk factor for prognosis. However, 
in the absence of convincing evidence on the impact of enteral feeding on survival, it is 
no surprise that there is variation regarding the timing of gastrostomy.  
For methodological and ethical reasons, it is difficult to demonstrate a survival 
advantage with enteral feeding. An accurate comparison can only be made with cases 
that require enteral nutrition but do not receive it. All studies evaluating the impact of 
enteral nutrition in MND are limited by absence of randomization. However, for 
obvious ethical reasons, a randomized controlled study cannot be undertaken in MND 
as it would be immoral to deny enteral feeding to those whom it is a necessity.  
Comparison can, therefore, only be made with patients who refuse the procedure but 
such patients are uncommon.  
 
5.4 Impact of enteral feeding on nutritional status 
The BMI stabilised following gastrostomy and this study adds to the limited literature 
on the positive impact of enteral feeding on nutritional status of MND patients.  An 
important observation relevant to clinical practice was that participants reported a sense 
of relief and security that their nutritional needs were met.  It is well recognised that 
malnutrition and weight loss can significantly impact QOL, as patients are often 
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exhausted, tired and spiritless (Greenwood, 2013; Korner et al., 2013). The findings of 
this study strongly indicate that management of malnutrition can play an important role 
not only in stabilising BMI/weight but also maintaining or enhancing QOL. 
 
5.5 Impact of enteral feeding on quality of life 
The major objective of enteral feeding as a supportive measure in MND is to optimise 
QOL rather than prolong survival (Chio et al., 1999; Mitsumoto and Del Bene, 2000). 
However, there is distinct lack of literature to support or refute enteral feeding for 
maintaining or improving QOL of MND patients. The perspectives of patients and their 
relatives are important in formulating nutritional management plans (Heffernan et al., 
2004). There is however, paucity of qualitative research in this area which would be 
useful in exploring subjective viewpoints of patients with MND in relation to enteral 
feeding.  
The commonly used QOL instruments do not provide explicit information regarding 
how nutritional issues are experienced, addressed and related to an individual patient’s 
QOL. Moreover, QOL in MND depends on a number of psychological and existential 
factors including the meaning that patients attach to their life, and therefore, an ideal 
QOL should encompass all these domains (Connolly et al., 2005; Robbins et al., 2001). 
However, the currently available QOL instruments do not address the impact of enteral 
feeding on all these domains of QOL in patients with MND.    
All three studies that have evaluated QOL in relation to enteral feeding provide 
retrospective data from studies that were not primarily intended to investigate the 
association between enteral feeding and QOL (Lou et al., 2010; Mitsumoto et al., 2003; 
Zamietra et al., 2012).  The only prospective study by Mazzini et al. (1995) did not 
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provide any concrete data relating to QOL. None of the studies have directly 
investigated the effect of enteral feeding on QOL.  
Apart from anecdotal impressions of enhanced QOL (Mazzini et al., 1995), the only 
available quantitative information relating to QOL is from the study by Mitsumoto et al 
(2003). 28% patient listed less fatigue or less time spent on meals and 17% listed 
improved psychological wellbeing as positive effects of enteral feeding (Mitsumoto et 
al., 2003). This may suggest that other factors such as reduction of the tiresome and 
prolonged meal teams may be important for patients.  
The prospective study described in chapter 4 provides rich qualitative data to support 
the view that enteral feeding improves QOL, a major goal of supportive management in 
MND. This is the first ever prospective study that has attempted to qualitatively 
investigate the impact of enteral feeding on QOL. A key finding relevant for clinical 
practice is that most study subjects acknowledged the importance of feeding tube and 
hence, the positive perception of enteral feeding. 
Despite the inconveniences including clinical complications, anxiety, dependence on 
others, social isolation and altered body image, the vast majority of patients reported 
improved QOL with enteral feeding. Enteral feeding was perceived as being essential to 
survival by some patients while others reported that it helped to facilitate travelling and 
save time and energy. Participants also reported a sense of relief and security that their 
nutritional needs were met.  Finally, participants had no regrets with gastrostomy 
insertion and no participant at 12 month follow up wished for the gastrostomy tube to be 
removed, indicating a positive attitude towards enteral feeding.  The positive impact 
may however, not be noticed within the first few months following gastrostomy 
insertion and enteral feeding.  
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5.6 Limitations 
This section will discuss the limitations of both the retrospective and prospective 
studies. These limitations will be exercised to draw recommendations for future work 
on enteral feeding in MND.  
A major limitation of the study exploring the characteristics of MND in Lancashire and 
South Cumbria is its retrospective nature. The Preston MND database was not initially 
constructed with the aim of investigating the association between enteral feeding and 
survival. Therefore, there is no mechanism for controlling the impact of potential 
confounders on survival. Information about vital capacity, timing of gastrostomy and 
percentage of weight loss at gastrostomy tube insertion could not be ascertained from 
the case notes. It therefore remains unclear whether gastrostomy was offered in line 
with the clinical guidelines on the topic.   
The retrospective study was also unable to ascertain the number of patients who were 
offered gastrostomy insertion and either refused or delayed the procedure. This would 
obviously have implications as gastrostomy placement late in the disease process, 
particularly when the forced vital capacity drops to less than 50% of the predicted, is 
associated with increased mortality.   
The prospective study investigating the impact of enteral feeding on QOL is also not 
without limitations. The sample size was small but reflective of an overall cohort of 
patients requiring enteral feeding and sufficient enough to generate meaningful results. 
It would be difficult to obtain a larger study sample given the low prevalence of MND 
patients requiring enteral feeding. A multicentre study would be ideally placed to 
address this shortcoming and build on the findings of this preliminary work.   
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It is of note that no specific criterion was used by the referring neurologists in making 
decisions about enteral feeding. In most cases, it was triggered by dysphagia but 
objective measures such as declining BMI and weight loss were used very infrequently. 
Although there was a significant (p<0.05) weight loss in the study cohort at the time of 
gastrostomy as compared to diagnosis, enteral feeding was recommended to only one 
patient on the basis of weight loss alone.   This echoes the findings of a survey 
conducted among neurologists from MND Centres in United Kingdom where measures 
of weight loss were the least used indicators in making decisions about enteral feeding 
(Stavroulakis et al., 2013). 
The ALSAQ-40 and Liverpool PEG questionnaires are also limited in their ability to 
explore the QOL of individual patients. The Liverpool PEG questionnaire has not 
undergone rigorous validation but it encapsulates a number of themes associated with 
the impact of enteral feeding on QOL.  This study also identified a major shortcoming 
of the PEG questionnaire. The crucial question “How much has the PEG affected QOL” 
is ambiguously worded as it is not explicit whether it implies a positive or negative 
effect on QOL. Moreover, these questionnaires do not explore all facets of enteral 
feeding that may be important to an individual patient.  In order to address this 
inadequacy, this study incorporated an open question to the Liverpool PEG 
questionnaire. This open question has generated rich data about the views and 
perspectives of patients regarding the impact of enteral feeding on their QOL. 
The participants were recruited from one care centre only and their views regarding the 
impact of enteral feeding on QOL may not necessarily reflect the experiences of MND 
patients from other centres. There is also the possibility of positively biased responses, 
given the unique service delivery model in the study centre where patients are supported 
at every stage of the disease process through provision of outreach and hospice clinics. 
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However, the service delivery model should not significantly influence the outcome as 
the questionnaire was specifically designed to address the impact of enteral feeding 
rather than the model of service delivery on QOL. Moreover, the clinical and 
demographic characteristics of MND in the study centre are highly consistent with data 
from other population based studies. It can therefore be convincingly argued that the 
study cohort is representative of the overall MND population. 
The lack of control group in the prospective study is an unavoidable limitation, as it 
would be unethical to deny enteral feeding to patients who require it, for the sole 
purpose of undertaking a study. A proportion of patients with MND defer or refuse 
gastrostomy insertion and it would be interesting to study the QOL outcomes of early 
enteral feeding as compared to late or no enteral feeding in patients who defer or refuse 
gastrostomy. Despite the limitations, this is the first study of its kind to explore the 
impact of enteral feeding on QOL of patients with MND.  
 
5.7 Conclusion 
Symptomatic and palliative treatment remains the mainstay of management in MND 
(Bede et al., 2011; Radunovic et al., 2007). In the absence of a cure, advance care 
planning is important to develop individualised care plans, particularly addressing 
decisions regarding nutritional support including enteral feeding (Chio et al., 2006; Ng 
et al., 2009). Achieving the best QOL for patients, their families and carers should be 
the primary goal of management (Radunovic et al., 2007).   
Enteral feeding may not improve survival, but this work demonstrates that it helps to 
maintain or even enhance QOL of MND patients.  Although clinicians cannot cure or 
halt the inexorable disease progression, they are distinctively placed to identify and 
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offer symptomatic treatments including nutritional support throughout the disease 
trajectory.  The topic of enteral feeding should be raised early in the disease process 
through a multidisciplinary approach to raise awareness about malnutrition, its 
consequences and management. Patients and their caregivers should be educated about 
the risks and benefits of enteral feeding and the optimal timing for insertion of feeding 
tube. The autonomy of the patient should, however, be respected throughout the care 
planning and delivery process (Radunovic et al., 2007). 
Nutritional management approaches including nutritional surveillance through 
measurement of BMI on a 3 monthly basis, dietary counselling and consideration of 
enteral feeding should therefore become an integral part of ongoing care (Andersen et 
al., 2012; Greenwood, 2013; Miller et al., 2009). Early involvement of dietician is 
imperative in nutritional assessment and management. Patients should be encouraged to 
record their decisions regarding enteral feeding as part of their care plan. These advance 
decisions will help to reduce the risk of gastrostomy placement, late in the illness, when 
invasive interventions can be potentially hazardous.   
Evidence-based information is of paramount importance in formulating treatment 
decisions regarding enteral feeding.  However, given the wide clinical heterogeneity of 
the disease, self-selection bias and ethical issues in randomising patients, the feasibility 
of randomised controlled trials on assessing the impact of enteral feeding on QOL is 
extremely limited. Furthermore, the rarity of the condition implies that it can take a 
single centre a number of years to accrue significant patient numbers into any study 
evaluating the efficacy of enteral feeding. The difficulty of undertaking randomised 
controlled trials in such a rare disease is a challenge to the international MND 
community to organise multicentre observational studies to address this contentious but 
fundamental issue.  
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The subject of enteral feeding in MND and its impact on survival and QOL has 
remained as much supposition as science. Multicentre studies will almost certainly be 
required to obtain a level of evidence sufficient to recommend enteral feeding for 
improving QOL.  In conclusion, until such evidence is forthcoming, the results from 
this work can help to inform nutritional management of patients with MND.  
 
5.8 Scope and recommendations for future research 
The thesis has identified the following topics for future research: 
1. Investigate the impact of deferring or refusing enteral feeding on QOL and 
survival of patients with MND in a prospective study. The study should be 
adequately powered and therefore, multicentre in nature. Undertaking a 
randomized controlled study may be difficult as it would be unethical to deny 
enteral feeding to those who need it.  However, it is well recognized that a 
proportion of patients with MND defer or refuse enteral feeding and identifying 
these patients early would allow an ethically acceptable control group. This 
would also allow comparison between QOL outcomes of early enteral feeding 
and late or no enteral feeding in patients who defer or refuse gastrostomy.     
2. Investigate the impact of enteral feeding on QOL of relatives and carers of 
patients with MND. It is becoming increasingly recognized that relatives and 
carers of patients with MND experience caregiver burden due to the rapid and 
progressive nature of the illness. The physical and psychological demands of 
caring for a patient with MND and subsequent bereavement can lead to 
significant caregiver strain with implications for QOL of relatives and carers. 
Providing assistance with enteral feeding can further add to the challenges of 
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caring for a patient with MND. Understanding these challenges and implications 
on QOL will be crucial in formulating appropriately tailored interventions 
including bereavement support that may help to improve the well-being and 
QOL of relatives and carers.  
3. Investigate the impact of enteral feeding on survival through prospective 
population based observational data. The systematic review has shown that none 
of the studies reporting the impact of enteral feeding on survival were primarily 
designed to determine the efficacy of enteral feeding as a therapeutic 
intervention. Moreover, there is marked heterogeneity in the rate of enteral 
feeding among various study centres with discernible variation in the criteria for 
recommending enteral feeding. For methodological and ethical reasons, it is 
difficult to demonstrate a survival benefit as factual comparison can only be 
made with patients that require enteral feeding but do not receive it. Comparison 
can however be made with patients who refuse the procedure but such patients 
are uncommon. This clearly highlights the need for multicentre studies 
specifically designed to evaluate the impact of enteral feeding on survival. Such 
studies should follow a uniformly agreed criterion for recommending enteral 
feeding.  
4. Explore the reasoning behind why some patients accept and others defer or 
reject enteral feeding. Unfortunately, some patients defer enteral feeding until 
late in the illness, when invasive interventions like gastrostomy can be 
potentially hazardous. Adult competent patients are entitled to refuse enteral 
feeding, but the reasons for this are unclear and may comprise social, cultural, 
support and personal factors including concerns about potential disadvantages of 
gastrostomy tube. Understanding these factors will be important to tailor 
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discussions around enteral feeding with patients to ensure that decisions around 
enteral feeding are timely and well informed.  
5. Incorporate health related QOL as an important end-point in studies involving 
enteral feeding in MND. Health related QOL is a multifaceted concept that aims 
to quantitatively evaluate the impact of illness as well as treatment on an 
individual, as different patients respond differently, both to illness and treatment. 
Management of MND is mainly supportive and palliative focussed on 
preserving and/or improving QOL. It is therefore important that QOL should be 
incorporated as a major outcome variable in studies involving enteral feeding in 
MND. 
6. Develop measurement tools to assess the impact of enteral feeding on QOL of 
patients with MND that encompasses not only the physical but also the 
emotional and social implications of enteral feeding. The measurement tool 
should also take into account the emotional impact of the disease itself, which 
has a fatal prognosis. Most of the commonly used QOL instruments are generic 
and not MND specific. Moreover, the currently available QOL instruments do 
not provide explicit information about how nutritional issues are experienced, 
addressed and related to an individual patient’s QOL. There is increasing 
evidence that QOL in MND does not seem to correlate with physical functioning 
but appears to depend on psychological, social support, spiritual and religious 
factors.  A MND specific QOL instrument should therefore not only address the 
domains included in ALSAQ – 40, but also incorporate the existential facet that 
will capture the meaning that patients attach to their life. Finally, such an 
instrument should also encapsulate the impact of nutritional issues including 
enteral feeding, where applicable, on the QOL of patients with MND.  
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5.9 Outputs from the research 
Some of the findings from the retrospective study were presented as a poster at the 25th 
International Symposium on ALS/MND held at Brussels in December 2014 (Appendix 
15). During the course of the study, three papers on MND, not directly related to the 
research were published (Appendix 16).  
The retrospective study presented in chapter 3 was submitted as a research paper 
entitled “Motor neurone disease in Lancashire and South Cumbria in North West 
England and an 8 year experience with enteral nutrition” to the Journal of Clinical 
Neuroscience for consideration for publication. This paper has been accepted and is 
currently with the production team of the Journal of Clinical Neuroscience.  
The prospective study presented in chapter 4 is being prepared as a paper entitled 
“Impact of enteral feeding on quality of life of patients with motor neurone disease” for 
submission to the Palliative Medicine journal for consideration for publication.  
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Appendix 1: Ovid MEDLINE search strategy 
 
Database: Ovid MEDLINE(R) <1946 to July Week 1 2014> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     exp Motor Neuron Disease/ (19962) 
2     motor neurone disease.mp. (709) 
3     motor$ neuron$ disease$.mp. or Motor Neuron Disease/ (6259) 
4     exp Amyotrophic Lateral Sclerosis/ (13109) 
5     lou gehrig.mp. (25) 
6     lou gehrig$.mp. (119) 
7     1 or 2 or 3 or 4 or 5 or 6 (21416) 
8     exp Enteral Nutrition/ (15730) 
9     enteral feeding.mp. or Enteral Nutrition/ (16792) 
10     feeding tube.mp. or Enteral Nutrition/ (16535) 
11     nasogastric feeding.mp. (430) 
12     exp Gastrostomy/ (6504) 
13     percutaneous endoscopic gastrostomy.mp. (2180) 
14     radiologically inserted gastrostomy.mp. (22) 
15     PEG.mp. (22852) 
16     RIG.mp. (2163) 
17     8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 (45517) 
18     7 and 17 (228) 
19     limit 18 to english language (196) 
 
*************************** 
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Appendix 2: Ovid EMBASE search strategy 
 
Database: Embase <1980 to 2014 Week 28> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     exp Motor Neuron Disease/ (27510) 
2     motor neurone disease.mp. (950) 
3     motor$ neuron$ disease$.mp. or Motor Neuron Disease/ (9277) 
4     exp Amyotrophic Lateral Sclerosis/ (22342) 
5     lou gehrig.mp. (35) 
6     lou gehrig$.mp. (165) 
7     1 or 2 or 3 or 4 or 5 or 6 (28624) 
8     exp Enteral Nutrition/ (20274) 
9     enteral feeding.mp. or Enteral Nutrition/ (21308) 
10     feeding tube.mp. or Enteral Nutrition/ (21947) 
11     nasogastric feeding.mp. (596) 
12     exp Gastrostomy/ (7459) 
13     percutaneous endoscopic gastrostomy.mp. (4693) 
14     radiologically inserted gastrostomy.mp. (52) 
15     PEG.mp. (35589) 
16     RIG.mp. (3131) 
17     8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 (67639) 
18     7 and 17 (484) 
19     limit 18 to english language (419) 
 
*************************** 
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Appendix 3: National Research Ethics Service (NRES) approval 
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Appendix 4: Lancashire Teaching Hospitals NHS  
Foundation Trust approval 
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Appendix 5: University of Central Lancashire approval 
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Appendix 6: Cox Regression analysis of non-enteral nutrition  
variables on survival time 
 
 
Covariate 
 
Regression 
coefficient (β) 
 
Degrees of 
freedom (df) 
 
p-value 
 
Odds Ratio 
Sex -0.086 1 0.44 0.92 
Onset age 0.03 1 0.001 1.03 
Onset site 0.17 1 0.15 1.19 
Riluzole -0.61 1 0.001 0.60 
Diagnostic Delay -0.002 1 0.001 0.998 
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Appendix 7: Letter of invitation to Participant 
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Appendix 8: Participant information sheet 
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Appendix 9: Reminder Letter to Participants 
 
199 
 
Appendix 10: Participant consent form  
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Appendix 11: Amyotrophic Lateral Sclerosis Functional Rating  
Scale – Revised    
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Appendix 12: Amyotrophic Lateral Sclerosis Assessment 
Questionnaire-40 (ALSAQ - 40) 
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Appendix 13: Letter to General Practitioner 
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Appendix 14: Liverpool PEG questionnaire 
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Appendix 15: Poster Presentation at the 25th International Symposium 
on ALS/MND held at Brussels in December 2014 
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Appendix 16: Publications on Motor Neurone Disease 
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